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Hexavalent chromium [Cr(VI)] compounds are redox cycling environmental carcinogens 
that induce apoptosis as the primary mode of cell death. Apoptosis is abnormally regulated 
in various disorders including cancer. Therefore, to understand the etiologies of these 
diseases, it is important to delineate the biochemical and molecular pathways involved in 
the regulation of apoptosis. The main objective of this study was to characterize the 
molecular mechanisms involved in Cr(VI)-induced apoptosis and malignant 
transformation. We found that both death receptor and mitochondrial pathways of 
apoptosis are involved in Cr(VI)-induced apoptosis, with the latter being more dominant. 
Consequently, overexpression of the mitochondrial anti-apoptotic protein Bcl-2 blocked 
Cr(VI)-induced apoptosis in human lung epithelial cells. We further observed that reactive 
oxygen species (ROS) play a critical role in Cr(VI)-induced apoptosis by acting through the 
mitochondrial death pathway. Superoxide anion (·O2‾) was found to be the major ROS 
involved in Cr(VI)-induced apoptosis that exerted its effect by degrading Bcl-2 protein 
through the ubiquitin-proteasomal pathway. Furthermore, nitric oxide (NO) scavenged ·O2‾ 
to form peroxynitrite (ONOO‾) and negatively regulated Cr(VI)-induced apoptosis. The 
mechanism by which NO exerted its anti-apoptotic effect involved upregulation of Bcl-2 
via S-nitrosylation that prevented its ubiquitination and subsequent proteasomal 
degradation. Additionally, we established an in vitro model for studying Cr(VI)-induced 
malignant transformation by subjecting non-tumorigenic human lung epithelial Beas-2B 
cell line to long-term Cr(VI) exposure. Cr(VI) transformed cells exhibited clear signs of 
malignancy such as loss of contact inhibition and increased colony formation as compared 
to the passage-matched original cell-line. Cr(VI) transformed cells showed decreased 
apoptosis and ROS production and increased NO as well as Bcl-2 expression. These 
observations confirmed that NO mediated stabilization of Bcl-2 is an important event in 
Cr(VI) induced carcinogenesis. Taken together, our study reveals a novel regulatory 
mechanism that could be important in apoptosis resistance in response to Cr(VI) exposure. 
Additionally, this study demonstrated Cr(VI)-induced malignant transformation of a human 
lung epithelial cell line, establishing an important in vitro model for studying the molecular 
mechanisms involved in Cr(VI)-induced carcinogenesis. This study provides new 
mechanistic insights about environmental carcinogen induced human lung cancer. Since 
Cr(VI) is a paradigm of carcinogenic transition metals, the inferences from this study may 
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1.1. Chromium Exposure  
Chromium (Cr) is a naturally occurring element found in rocks, animals, plants, soil, 
volcanic dust, gases and living organisms (1, 2). Chromium commonly occurs in the 
trivalent [Cr(III)] and hexavalent [(Cr(VI)] forms. Cr(III) compounds are normal dietary 
constituents that affect sugar metabolism by potentiating insulin action via interaction with 
the insulin receptor on the cell surface, and act as a cofactor in the maintenance of normal 
lipid and carbohydrate metabolism (3-5). Cr(III) compounds are considered non-toxic, non-
carcinogenic and non-mutagenic as they are poorly absorbed (6, 7). On the other hand, 
Cr(VI) compounds are strongly associated with adverse health effects such as lung cancer. 
Exposure to Cr(VI) has been associated with the induction of lung cancer in workers 
employed in chrome plating, electroplating, leather tanneries, pigment manufacturing and 
stainless steel welding (8-11). Non-occupational and environmental exposure to Cr occurs 
from areas near landfills, chromate industries, hazardous waste disposal sites, automobile 
emissions and cigarette smoke (1). In United States (US), increased incidence of lung 
cancer has been reported in smokers with Cr(VI) exposure, with average cigarettes 
containing 0.24/6.3 mg Cr/kg as estimated by the International Agency of Research on 
Cancer (IARC) (9, 12). Cr(VI) compounds are classified as Group I human carcinogens by 
IARC in 1990 (12). The carcinogenic potential of Cr(VI) depends upon various factors 
such as water solubility, chemical speciation and involvement of reactive oxygen species 
(ROS) (13). Although Cr(VI) does not interact with isolated DNA directly, it is 
carcinogenic as it can actively enter cells, in contrast to Cr(III), by non-specific anionic 
transport system (2). Inside the cell, it is metabolically reduced to its lower oxidation states. 
These intermediates, specifically Cr(III), together with oxidative stress and a cascade of 
cellular events are involved in Cr(VI)-induced toxicity and cell death (Fig. 1) (14). In the 
cells, Cr(III) is the ultimate DNA binding species of Cr but Cr(III) compounds are 
considered non-carcinogenic as they can not enter cells through the cell membrane 
transporters (15). Cell death induced by Cr(VI) occurs primarily through apoptosis (16), 
and its abnormal regulation has been associated with the initiation of Cr(VI)-induced 
cancer(17). It has been suggested that Cr(VI) exposure may result in cell cycle arrest, 
neoplastic transformation, and apoptosis induction (14, 18). However, the molecular 
mechanisms involved in Cr(VI)-induced apoptosis and carcinogenesis are largely 
unknown.  
 
1.2. Apoptosis Signaling Cascades 
Under normal conditions, cell cycle proceeds without interruptions. However, cell cycle 
surveillance mechanisms sets checkpoints for cell cycle progression and if the cells are 
damaged genetically or functionally, they undergo arrest in the G1 phase of the cell cycle 
where the damaged cell is repaired before they enter the replication phase. Nevertheless, if 
the cells are damaged beyond repair they undergo programmed cell death, i.e., apoptosis. 
Apoptosis is a regulated physiological process leading to cell death characterized by cell 
shrinkage, membrane blebbing and DNA fragmentation (19). Caspases, a family of 
cysteine proteases, are central regulators of apoptosis. Initiator caspases such as caspase-8 
and -9 activate downstream effector caspases and apoptosis (20, 21). Caspase-8 and -9 are 
the key pro-apoptotic proteins of the two major pathways regulating apoptosis, viz., the 
intrinsic pathway (mitochondria) and the extrinsic pathway (death receptor) (Fig. 2). 
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1.2.1. Extrinsic pathway - This pathway of apoptosis is induced via signaling through a 
family of death receptors including Fas (CD95/APO-1) and tumor necrosis factor receptor  
- 1 (TNFR-1). Death receptor ligands characteristically initiate signaling by recruiting 
specialized adaptor proteins to their cytosolic death domains resulting in the recruitment of 
procaspase-8 to the death-inducing signaling complex (DISC) causing activation of 
caspase-8 (22-24). Activated caspase-8 stimulates apoptosis via two parallel cascades 1) by 
direct cleavage and activation of caspase-3 leading to apoptosis, and 2) by cleavage of Bid 
(a Bcl-2 family protein) leading to apoptosis through the intrinsic pathway.  
1.2.2. Intrinsic pathway - This pathway can be induced by pro-apoptotic Bcl-2 family of 
proteins such as Bid, Bax and Bad that reside in the cytosol but translocate to the 
mitochondria following death signaling. In the mitochondria they promote the release of 
cytochrome c, which then binds to apoptotic protease activating factor 1 (Apaf 1) and 
forms an activation complex (apoptosome) with procaspase-9 leading to its cleavage and 
activation in the form of caspase-9 (25, 26). Caspase-9 activates effector caspases such as 
caspase-3 leading to apoptosis. The mitochondrial pathway is also activated when cytosolic 
Bid is cleaved by caspase-8 following signaling through the activation of death receptor 
(27-29). Its active fragment or truncated Bid (tBid) translocates to the mitochondria, 
inducing cytochrome c release, which sequentially activates caspases-9 and -3 leading to 
cell death by apoptosis (Fig. 2). 
1.3. Apoptosis Regulatory Proteins 
The apoptotic pathways are regulated at different levels by various proteins including 
FLICE-inhibitory protein (FLIP) and B-cell lymphoma-2 (Bcl-2). FLIP proteins are the 
regulators of the extrinsic death receptor pathway. These anti-apoptotic proteins are 
recruited to the DISC upon stimulation where they prevent procaspase-8 recruitment and 
processing, preventing apoptosis through the extrinsic pathway (30-32). FLIP is involved in 
rendering cells resistant to death receptor-mediated apoptosis in various cell types and 
elevated expression of FLIP is associated with tumor cells that can escape from immune 
surveillance in vivo (33-36). Bcl-2 is a key apoptosis-regulatory protein of the 
mitochondrial death pathway (25). Formation of heterodimers with pro-apoptotic proteins 
such as Bax, inhibition of cytochrome c release, and regulation of the mitochondrial 
transmembrane potential are some of the mechanisms by which Bcl-2 exerts its anti-
apoptotic effect (37-39). The anti-apoptotic function of Bcl-2 is closely associated with its 
expression levels, which is regulated by various mechanisms, including proteasomal 
degradation. Selective modification of ε-NH2 groups of lysine residues in the protein ready 
for degradation by ubiquitination is the initial step that targets the protein for degradation 
by the proteasome complex (40, 41). Various factors such as specific structural features, 
phosphorylation or a partially conserved sequence motif are implicated in making proteins 
susceptible to degradation (42). However, the physiological signals that lead to protein 
recognition by ubiquitin and degradation via the proteasomal pathway are unclear. The 
importance of Bcl-2 and FLIP in the development of apoptosis resistant phenotype and 
neoplastic development has been established. However, their role in Cr(VI)-induced 
apoptosis and carcinogeneis is largely unknown. 
 
1.4. Reactive oxygen species (ROS) 
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ROS such as hydrogen peroxide (H2O2), superoxide anion (·O2‾), and hydroxyl radical 
(·OH) are the byproducts of normal oxygen metabolism which participate in normal cell 
functions and act as intracellular signaling molecules in many biological processes (43, 44). 
However, excessive production of ROS may cause DNA damage and abnormal activation 
of certain cell growth regulators, thereby leading to carcinogenesis (43). Mitochondria are 
the primary but not the only source of ROS during apoptosis. The release of cytochrome c 
in response to various apoptotic stimuli disrupts the mitochondrial electron transport chain 
as cytochrome c is responsible for the transfer of electrons from complex III to IV (45). 
This leads to the generation of ·O2‾ as a result of the leakage of electrons due to the 
disruption of mitochondrial respiratory chain (45, 46). Cellular redox state plays a major 
role in its response to external stimuli, induction or inhibition of apoptosis. Cr(VI) 
compounds are redox cycling carcinogens that are reduced by certain flavoenzymes such as 
glutathione reductase to generate Cr(V), Cr(IV) and Cr(III) in the cellular system (Fig. 1) 
(17, 47-50). During this process, molecular oxygen is reduced to ·O2‾, which generates 
H2O2 via dismutation. The resultant lower oxidation state intermediates react with H2O2 
generating ·OH radical via a Haber-Weiss or Fenton like reaction (49) (Fig.1). Thus, during 
the cellular reduction of Cr(VI), along with the reduced intermediates, a whole spectrum of 
ROS are generated that cause diverse cytotoxic and genotoxic effects including DNA 
damage, mutagenesis, growth arrest and cell death (51). Although various studies have 
shown the involvement of ROS in Cr(VI)-induced apoptosis, its relationship with the well 
studied caspase activation are not established. 
 
1.5. Nitric oxide (NO) 
NO is an important signaling molecule produced endogenously in a NADPH-dependent 
reaction catalyzed by constitutively expressed or inducible NO synthases from the 
guanodino group of L-arginine (52). There are 3 different genes encoding NO synthases 
including 1) nNOS/NOS-1 (neuronal NOS) found in the neurons, 2) iNOS/NOS-2 
(inducible NOS) found in macrophages, epithelial cells, T cells, endothelial cells and 
eosinophils, and eNOS/NOS-3 (endothelial NOS) found in the endothelial cells lining the 
lumen of blood vessels (53). The physiological levels of constitutively expressed NOS 
remain relatively steady, whereas in response to an appropriate stimuli, iNOS catalyzes the 
production of much higher levels of NO (53). NO is a multifunctional free radical that 
diffuses freely across cell membranes and interacts with many other molecules. For 
instance, it reacts rapidly with ·O2‾ in a diffusion controlled reaction to primarily form 
peroxynitrite (ONOO¯) in most cell systems (54). ONOO¯ is a potent and versatile oxidant 
that can attack a wide range of biological molecules. It is believed that the formation of 
ONOO¯ anions due to the overproduction of NO is the main culprit in most of the diseases 
related to NO. ONOO¯ plays a role in mediating cytotoxicity through alterations in protein, 
lipids and nucleic acid structure and function with resultant disruption of cellular 
homeostatic mechanisms leading to diseased conditions. The effects of ONOO¯ on protein 
function are mainly due to its reactivity and covalent modification of tyrosine and/or 
cysteine residues (55). One of the well-established mechanisms by which NO, through the 
formation of ONOO¯, regulates the function of various target proteins is via S-nitrosylation 
(56). This post-translational modification of proteins can positively or negatively regulate 
various signaling pathways, proteins, and metabolic processes (57). Thus, NO exhibits 
various physiological as well as pathophysiological effects. Subtle changes in its rate of 
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production may critically impact cellular homeostasis, consequently initiating a variety of 
cellular signaling processes, including apoptosis (58). Depending on a variety of factors, 
including the flux and dose of NO, type of cells involved and redox state of the cell, NO 
has been demonstrated to have both pro- and anti-apoptotic role (52). Even though NO has 
been widely implicated in apoptosis and its dysregulation, its role in carcinogenesis is not 
well characterized. In particular, the role of NO in Cr(VI)-induced apoptosis has never been 
elucidated.  
 
1.6. Cr(VI)-induced malignant transformation 
Lung cancer is the leading cause of cancer mortality worldwide and yet the etiology of lung 
cancer is poorly understood. Current research indicates that long-term exposure to inhaled 
carcinogens has the greatest impact on risk of lung cancer. Exposure to Cr(VI) is associated 
with the incidence of lung cancer in humans. Several epidemological studies in the last few 
decades have associated exposure to Cr(VI) with the induction of lung cancer in workers in 
various occupational settings (8-11). In US, a recent air quality survey indicated that people 
in several residential areas are exposed to particulate airborne chromium at concentrations 
exceeding 100 times the chronic toxicity benchmark (59). Therefore, in addition to 
occupational exposure, environmental chromium is an emerging concern and is associated 
with long-term carcinogenic effect of the lungs. However, these observations are not 
supported by animal data. Several groups have established in various animal models that 
exposure to Cr(VI) compounds demonstrated no significant increase in lung tumors as 
compared to untreated control (60-62) and the reason for this discrepancy is not 
understood. It is widely believed that human lung cancer manifests mostly as epithelial cell 
derived carcinomas (14); however, it is still unknown whether human lung epithelial cells 
are directly susceptible to Cr(VI)-induced malignant transformation. This is due to the lack 
of a good model to study the molecular mechanisms of Cr(VI)-induced apoptosis and 
malignant transformation. Abnormal apoptosis regulatory mechanisms and ROS generation 
are considered as important factors in neoplastic development in response to Cr(VI). 
However, the molecular mechanisms underlying Cr(VI)-induced apoptosis and malignant 






























































































FIGURE 2. Diagrammatic illustration of the death receptor pathway and 

















1.7. SUMMARY  
 
 Cr(VI) compounds are ubiquitous environmental carcinogens that primarily induce 
cell death via apoptosis. Mitochondria-mediated intrinsic pathway and death 
receptor-mediated extrinsic pathway are the two major signaling cascades of 
apoptosis. However, the relative importance of these pathways in Cr(VI)-induced 
apoptosis are largely unknown.  
 Bcl-2 and FLIP are key regulatory proteins of the intrinsic and extrinsic pathways, 
respectively. The relative importance of these apoptosis regulatory proteins in 
response to Cr(VI) exposure is largely unknown. Since defects in apoptosis 
regulatory mechanisms lead to neoplastic development, it is important to 
understand the role of these key proteins in Cr(VI)-induced apoptosis.  
 Activation of apoptosis is tightly linked with generation of ROS. ROS have been 
implicated in the regulation of Cr(VI)-induced apoptosis and carcinogenicity. 
However, the identity of specific ROS, precise source of ROS and the underlying 
mechanism are largely unknown. The elucidation of the regulatory mechanisms of 
apoptosis by ROS is crucial in understanding Cr(VI)-induced carcinogenesis.  
 Exposure to Cr(VI) is associated with the incidence of lung cancer in humans. 
Elevated levels of NO have been reported in human lung cancers (63-68). However, 
the role of NO in Cr(VI)-induced apoptosis and malignant transformation has not 
been elucidated.  
 Lung cancers mostly manifests as epithelial cell derived carcinomas; however, it is 
still unknown whether human lung epithelial cells are directly susceptible to 
Cr(VI)-induced malignant transformation. This is due to the lack of a good model 
system to study the molecular mechanisms involved in Cr(VI)-induced malignant 
transformation. 
 
1.8. SPECIFIC AIMS 
 
The objective of this study was to characterize the molecular mechanisms of Cr(VI)-
induced apoptosis and malignant transformation. To achieve this goal we accomplished the 
following specific aims: 
Aim I: Delineate the signaling cascades and identify the key apoptosis-regulatory proteins 
involved in Cr(VI)-induced apoptosis. 
 
Aim II: Identify specific ROS, their cellular sources, and the mechanism by which ROS 
regulates Cr(VI)-induced apoptosis. 
 
Aim III: Study the role of NO in Cr(VI)-induced apoptosis and determine the underlying 
mechanisms. 
 
Aim IV: Establish a model to study Cr(VI)-induced malignant transformation and study 
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Signaling Cascades Involved in Cr(VI)-Induced Apoptosis and 
























Cr(VI) compounds are redox cycling carcinogens that induce apoptotic cell death. Since 
defects in apoptosis regulatory mechanisms contributes to increased resistance to apoptosis 
induced by Cr(VI), it is critical to understand the molecular mechanisms involved in 
Cr(VI)-induced apoptosis. Activation of apoptosis is tightly linked with the generation of 
ROS. Likewise, ROS have been implicated in the regulation of Cr(VI)-induced apoptosis 
and carcinogenicity. However, the mechanism involved, the identity of specific ROS and 
the cellular source of ROS are largely unknown. The objective of this study was to 
characterize the signaling pathways of Cr(VI)-induced apoptosis and evaluate the role of 
ROS in this process. We observed that both extrinsic and intrinsic pathway are involved in 
Cr(VI)-induced apoptosis and there is a potential cross-talk between the two pathways. 
Further, it was found that the mitochondrial pathway is more dominant in response to 
Cr(VI) exposure. Consequently, overexpression of the mitochondrial anti-apoptotic protein 
Bcl-2 blocked Cr(VI)-induced apoptosis significantly as compared to Flip, which had 
minimal effect. Recent evidences suggest that Bcl-2 protein inhibits apoptosis by 
suppressing free radicals generation or by regulating cellular antioxidant defense 
mechanisms. In this study, we also found that ROS, specifically superoxide (·O2‾), 
mediates Cr(VI)-induced apoptosis of human lung epithelial H460 cells. ·O2‾ exerted its 
effect by degrading Bcl-2 protein through the ubiquitin-proteasomal pathway. H460 ρ0 
cells that lack mitochondrial DNA and a functional electron transport demonstrated a 
significant decrease in ROS production and apoptosis indicating that mitochondria is the 
major source of ROS in Cr(VI)-induced apoptosis of H460 cells. This study gives a 
mechanistic understanding of ROS-mediated Bcl-2 downregulation and apoptosis induction 
providing critical insight into the pro-oxidant role of Cr(VI) and the basis for differential 
























Hexavalent chromium compounds are ubiquitous environmental carcinogens that have 
been listed as Group I human carcinogens by IARC in 1990 (1).  Exposure to Cr(VI) has 
been associated with induction of lung cancer in various occupational settings (2-5). Non-
occupational exposure to Cr(VI) compounds occurs from cigarette smoke, automobile 
emissions, areas of landfills and hazardous waste disposal sites (1, 3, 6). Cr(VI) has been 
shown to induce chromosomal aberrations, mutations, and transformations in cultured 
mammalian cells (7, 8), and a variety of DNA lesions such as strand breaks, DNA protein 
cross-links, DNA base modification leading to cell death (9-12). Cell death induced by 
Cr(VI) occurs primarily through apoptosis (13), and its abnormal regulation has been 
associated with the initiation of Cr(VI)-induced cancer (14). Apoptosis is a tightly 
regulated process characterized by shrinkage of the nucleus, blebbing of membranes, 
condensation or fragmentation of chromatin that eliminates damaged cells maintaining 
tissue homeostasis (15, 16). In general, two major pathways of apoptosis have been 
recognized; the mitochondria-mediated intrinsic pathway and death receptor-mediated 
extrinsic pathway. The extrinsic pathway of apoptosis is induced via signaling through a 
family of death receptors such as Fas and TNFR-1, connecting ligand binding at the cell 
surface to apoptosis induction (17-19). The intrinsic pathway is induced by pro-apoptotic 
proteins belonging to the Bcl-2 family of proteins that reside in the cytosol but translocate 
to the mitochondria following death stimuli and promote the release of cytochrome c 
leading to apoptosis (20, 21). The mitochondrial pathway is also activated following 
signaling through death receptor and caspase-8 that causes the cleavage, translocation and 
activation of Bid, which sequentially activates caspases-9 and caspase-3 leading to 
apoptosis (22-24). Therefore, there is a potential cross-talk between the two apoptotic 
pathways. Both apoptotic pathways are regulated at different levels by various proteins 
including Bcl-2 and FLIP. The anti-apoptotic protein FLIP is the key regulator of the 
extrinsic pathway. It is recruited to the DISC upon stimulation where it prevents 
procaspase-8 recruitment and processing (25-27). The anti-apoptotic protein Bcl-2 resides 
in the outer mitochondrial wall and regulates apoptosis by controlling mitochondrial 
permeability and the release of cytochrome c, thus, inhibiting apoptosis (20, 28, 29). Bcl-2 
and Flip proteins are overexpressed in a variety of cancers and play a key role in these 
malignancies. However, the role of Bcl-2 and FLIP in Cr(VI)-induced caspase activation 
and apoptosis is largely unknown. Identifying the key mechanisms and apoptosis 
regulatory proteins involved in Cr(VI)-induced apoptosis are critical in understanding the 
development of apoptosis resistance phenotype in response to Cr(VI) exposure. However, 
the detailed mechanism of apoptosis in response to Cr(VI) has not been systemically 
investigated.  
 
Several reports indicate that ROS can cause cell death via apoptosis (30, 31). ROS such as 
hydrogen peroxide (H2O2), superoxide anion (·O2‾), and hydroxyl radical (·OH) are the 
byproducts of normal oxygen metabolism which act as intracellular signaling molecules in 
many biological processes (32, 33). However, excessive production of ROS may cause 
DNA damage and abnormal activation of certain cell growth regulators, thereby leading to 
carcinogenesis (32). Although recent evidences suggest that ROS have been implicated in 
the regulation of Cr(VI)-induced apoptosis and carcinogenicity, the mechanisms of 
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carcinogenesis are not yet clear (34-36). In the case of Cr(VI) compounds, cellular 
reduction leads to the generation of ·O2‾ along with the formation of lower oxidation state 
intermediates (14, 37, 38). ·O2‾ is further converted to H2O2 via dismutation, which reacts 
with the resultant intermediates to generate ·OH radicals. ROS generated during the one-
electron reduction of Cr(VI) along with a cascade of cellular events causes diverse 
cytotoxic and genotoxic effects including DNA damage, mutagenesis, growth arrest and 
cell death (10). Programmed cell death or apoptosis can be modulated by the changes in the 
expression of distinct sets of genes (15). The proto-oncogene Bcl-2 is one of the major 
genes regulating apoptotic cell death. The anti-apoptotic function of Bcl-2 is regulated by it 
expression levels. Various mechanisms including dimerization, phosphorylation, 
degradation and post-translational modification regulate the stability and expression levels 
of Bcl-2 protein (39, 40). Degradation of Bcl-2 is mainly mediated through the ubiquitin-
proteasomal pathway (39, 40). In vitro and in vivo studies suggest that Bcl-2 blocks 
apoptosis through regulation of cellular antioxidant defense mechanisms or by suppressing 
production of free radicals thus acting as an antioxidant (41-43). Even though ROS has 
been implicated in Cr(VI)-induced apoptosis, the cellular source of ROS generation and its 
relationship with the well-studied caspase activation has not been established.  
 
The aim of this study was to delineate the signaling cascades involved in Cr(VI)-induced 
apoptosis and evaluate the role of ROS in this process. We found that both extrinsic and 
intrinsic pathway are involved in Cr(VI)-induced apoptosis and there is a potential cross-
talk between the two pathways. Further, mitochondrial pathway of apoptosis was more 
dominant in response to Cr(VI) and consequently, overexpression of Bcl-2 blocked Cr(VI)-
induced apoptosis significantly. Further, it was observed that generation of ROS induces 
apoptotic cell death in response to Cr(VI) exposure and ·O2‾ is the major ROS involved in 
Cr(VI)-induced apoptosis. Although, cytosolic ROS is involved, mitochondria is the major 
cellular source of ROS involved in Cr(VI)-induced apoptosis. Further, it was observed that 
·O2‾ mediated its pro-apoptotic effect by causing down-regulation and degradation of Bcl-2 
through the ubiquitin-proteasomal pathway thus inducing apoptosis through the 
mitochondrial pathway. The elucidation of the regulatory mechanisms of apoptosis by ROS 
is crucial in understanding carcinogenesis induced by genotoxic agents such as chromium. 
This study showing the role of ·O2‾ in Cr(VI)-induced cell death and Bcl-2 downregulation, 
documents a novel mechanism of apoptosis induction by Cr(VI) involving Bcl-2 stability 
linked to ·O2‾  generation.  This study forms the basis of the mechanisms involved in the 
development of apoptosis resistant phenotype in response to Cr(VI) and can be exploited 
further to understand the molecular mechanisms involved in Cr(VI)-induced malignant 










2.3. Materials and Methods 
 
Chemicals and Reagents 
N-acetyl cysteine (NAC), 6-Anilinoquinoline-5,8-quinone (LY-83,583), Hydrogen 
peroxide (H2O2), Xanthine, Xanthine oxidase, rotenone, diphenylene iodonium (DPI), 
lactacystin (LAC), ethidium bromide, sodium pyruvate, uridine and sodium dichromate 
(Na2Cr2O7.2H2O) [Cr(VI)] were obtained from Sigma Chemical Inc. (St. Louis, MO). 
Fluorogenic caspase substrates IETD amino-4-methylcoumarin (IETD-AMC), LEHD-
AMC, caspase-8 inhibitor (z-IETD-FMK), caspase-9 inhibitor (z-LEHD-FMK), pan-
caspase inhibitor (zVAD.FMK) and Flip antibody were from Alexis Biochemicals (San 
Diego, CA). Cell-permeable superoxide dismutase (SOD) mimetic, Mn(III)tetrakis (4-
benzoic acid) porphyrin (MnTBAP), was purchased from Calbiochem (La Jolla, CA), and 
catalase was from Boehringer Mannheim (Indianapolis, IN). The oxidative probes, 
dichlorofluorescein diacetate (DCF-DA) and dihydroethidium bromide (DHE), and the 
apoptosis dye Hoechst 33342 were from Molecular Probes (Eugene, OR). Antibodies for 
caspase-8, caspase-9 and Bid were from Cell Signaling Technology, Inc. (Danvers, MA).  
Antibodies for Bcl-2, peroxidase-labeled secondary antibodies, anti-myc agarose beads, 
and protein A-agarose were from Santa Cruz Biotechnology (Santa Cruz, CA).  Antibodies 
for ubiquitin, and β-actin were from Sigma (St. Louis, MO) and the transfecting agent 
Lipofectamine 2000 was from Invitrogen (Carlsbad, CA).  
 
Cell Culture 
The human lung epithelial cancer NCI-H460 cell line was obtained from the American 
Type Culture Collection (ATCC) (Rockville, MD).  Cells were cultured in RPMI 1640 
medium (Sigma, St. Louis, MO) containing 5% fetal bovine serum, 2 mM L-glutamine, 
100 units/ml penicillin and 100 µg/ml streptomycin in a 5% CO2 environment at 37ºC. 
Cells were passaged at preconfluent densities using a solution containing 0.05% trypsin and 
0.5 mM EDTA (Invitrogen).  
 
Caspase Assay 
Caspase activity was determined by fluorometric assay using the enzyme substrate IETD-
AMC for caspase-8 and LEHD-AMC for caspase-9, which are specifically cleaved by the 
respective enzymes at the Asp residue to release the fluorescent group, AMC. Cell extracts 
containing 20 µg of protein were incubated with 100 mM HEPES containing 10% sucrose, 
10 mM dithiothreitol, 0.1% 3-((3-cholamidiopropyl)-1) propane sulfonate, and 50 µM 
caspase substrate in a total reaction volume of 0.25 ml. The reaction mixture was incubated 
for 60 min at 37°C and quantified fluorometrically at the excitation and emission 




After specific treatments, apoptosis was determined by incubating cells with 10 µg/ml 
Hoechst 33342 nuclear stain for 30 min at 37°C and scoring the percentage of cells having 
intensely condensed chromatin and/or fragmented nuclei by fluorescence microscopy 




H460 cells were seeded in 60-mm dishes until they reached 80% confluence. The cells 
were then transiently transfected in serum free medium with the expression plasmids 
encoding Flip or Bcl-2 and green fluorescent protein using Lipofectamine 2000 reagent. 
After 10 h, the medium was replaced with culture medium containing 5% fetal bovine 




Stable transfectants of Flip, Bcl-2, glutathione peroxidase (GPx) and superoxide dismutase 
(SOD) were generated by culturing H460 cells in six-well plates until they reached 80% 
confluence. 1 µg of cytomegalovirus-neo vector and 15 µl of Lipofectamine 2000 reagent 
with 2 µg of Flip, Bcl-2, GPx, SOD, or control pcDNA3 plasmid were used to transfect the 
cells in the absence of serum. After 10 h, the medium was replaced with culture medium 
containing 5% fetal bovine serum. Approximately 36 h after the beginning of the 
transfection, the cells were digested with 0.03% trypsin, and the cell suspensions were 
plated onto 75 ml culture flasks and cultured for 24 to 28 days with G418 selection (400 
µg/ml). Stable transfectants were identified by Western blot analysis and were cultured in 
G418-free RPMI 1640 medium for at least two passages before each experiment. 
 
ROS Detection 
Intracellular peroxide and superoxide production was determined by flow cytometry and 
fluorescence microscopy using DCF-DA and DHE fluorescence probes, respectively.  For 
flow cytometric analysis, cells (1x106/ml) were incubated with the fluoresecent probes (10 
µM) for 30 min at 37ºC, after which they were washed, resuspended in phosphate buffered 
saline (PBS), and analyzed for DCF (494/519 nm) and DHE fluorescence (535/617 nm) 
using FACS calibur, (Becton-Dickinson, Rutherford, NJ). The median fluorescence 
intensity was quantitated by CellQuest software (Becton-Dickinson) analysis of the 
recorded histograms. For fluorescence microscopy, cells were incubated with the probes as 
described above and then examined for DCF and DHE fluorescence using Carl Zeiss 
Axiovert microscope. 
 
Derivation of ρ0 cells 
H460 ρ0 were prepared as previously described (44). Briefly, H460 cells were cultured in 
the presence of ethidium bromide (100 ng/ml) to inhibit mitochondrial DNA replication for 
more than 20 generations until use (ρ0 cells). ρ0 cells were derived and maintained in 
complete medium supplemented with 100 µg/ml uridine and 100 µg/ml pyruvate. 
 
Western Blotting 
After specific treatments, cells were incubated in lysis buffer containing 20 mM Tris-HCl 
(pH 7.5), 1% Triton X-100, 150 mM NaCl, 10% glycerol, 1 mM Na3VO4, 50 mM NaF, 
100 mM phenylmethylsulfonyl fluoride (PMSF), and protease inhibitor mixture for 20 min 
on ice. After insoluble debris was precipitated by centrifugation at 14,000 x g for 15 min at 
4°C, the supernatants were collected and assayed for protein content using bicinchoninic 
acid (BCA) method. Equal amount of proteins per sample (15 µg) were resolved on 10% 
SDS-PAGE and transferred onto a 0.45-µm nitrocellulose membrane. The transferred 
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membranes were blocked for 1 h in 5% non-fat dry milk in TBST (25 mM Tris-HCl, pH 
7.4, 125 mM NaCl, 0.05% Tween 20) and incubated with the appropriate primary 
antibodies and horseradish peroxidase-conjugated secondary antibodies. The immune 
complexes were detected by chemiluminescence (Supersignal, West Pico; Pierce) and 
quantified by imaging densitometry using UN-SCAN-IT automated digitizing software 
(Silk Scientific Corp.).  Mean densitometry data from independent experiments were 
normalized to the control.  The data were presented as mean ± S.D. and analyzed by 
Student’s t test. 
 
Immunoprecipitation 
Stable H460 cells overexpressing Bcl-2 were washed after treatments with ice-cold PBS 
and lysed in lysis buffer (20 mM Tris (pH 7.4), 150 mM NaCl, 10% glycerol, 0.2% NP40, 
100 mM PMSF and a commercial protease inhibitor mixture) at 4°C for 20 min.  After 
centrifugation at 14,000 x g for 15 min at 4oC, the supernatants were collected and the 
protein content was determined by BCA protein assay. Cleared lysates were normalized 
and 60 µg proteins were incubated with 8 µl of anti-myc agarose bead (Santa Cruz 
Biotechnology) diluted with 12 µl protein A-agarose for 4 h at 4oC. The immune 
complexes were washed 3 times with 500 µl lysis buffer, resuspended in 2x Laemmli 
sample buffer and boiled at 95oC for 5 min. The immune complexes were separated by 






























Cr(VI) Induced Cell Death – Cr(VI)-containing compounds are ubiquitous environmental 
carcinogens that induce apoptosis as the primary mode of cell death (13). To characterize 
the signaling pathways involved in Cr(VI)-induced apoptosis, we first characterized the 
apoptotic response to Cr(VI) treatment in human lung epithelial H460 cells. Cells were 
treated with different doses of Cr(VI) (0-100 µM), and apoptosis was determined after 12 h 
by Hoechst 33342 assay. Figs. 1, A and B, show that Cr(VI) treatment caused a dose-
dependent increase in cell apoptosis over control level, as indicated by increased nuclear 
fluorescence and chromatin condensation of the treated cells. Cells were also treated with 
zVAD, a pan-caspase inhibitor, in addition to Cr(VI). Figs. 1, C and D, show that zVAD 
treatment blocked Cr(VI)-induced apoptosis, reducing it to control levels. This indicated 
that Cr(VI) induces apoptosis through the classical caspase dependent pathways. 
 
Signaling Pathways Induced by Cr(VI) – Various studies have demonstrated that caspase-8 
and caspase-9 represent the apical caspases in the death receptor and mitochondrial 
pathways, respectively (45-48).  Therefore, to investigate the potential involvement of the 
extrinsic and intrinsic pathway in Cr(VI)-induced apoptosis, cleavage and activation of 
caspase-8 and caspase-9 in response to Cr(VI) exposure was analyzed by Western blotting 
and caspase activation assays. Western blot analysis showed that both apoptotic pathways 
were activated in response to Cr(VI) (Figs. 2, A and B). Additionally, we also observed that 
Bid protein was cleaved and activated (tBid) in response to Cr(VI), suggesting a potential 
cross-talk between the two apoptotic pathways. Since caspase activation leads to the 
activation of Bid, this indicates that  H460 cells are Type II cells  (Fig. 2C).  
 
Caspase Activation Induced in Response to Cr(VI) Exposure – Caspase activity assays 
confirmed that Cr(VI) induced both caspase-8 and caspase-9 activation. Furthermore, it 
demonstrated that the mitochondrial pathway is more dominant in response to Cr(VI) 
exposure (Fig. 3A). Since caspase-8 and caspase-9 are the key marker proteins of the death 
receptor pathway and mitochondrial pathway, the results of this study suggest that the 
mitochondrial pathway is the major apoptotic pathway induced in response to Cr(VI) 
exposure. Control studies using specific caspase-8 inhibitor (IETD-CHO) and caspase-9 
inhibitor (LEHD-CHO) indicate the specificity of caspase activation under the test 
conditions (Fig. 3B). It was also observed that both caspase inhibitors reduced apoptosis to 
the control levels further confirming the involvement of caspases in Cr(VI)-induced 
apoptosis (Fig. 3C). 
 
Effect of Cr(VI) on Apoptosis Regulatory Proteins – Bcl-2 is the key apoptosis-regulatory 
protein of the mitochondrial death pathway and FLIP is the key protein of the death 
receptor pathway (20, 25-29). To determine the effect of Cr(VI) exposure on these proteins, 
cells were treated with various doses of Cr(VI) and analyzed for Flip and Bcl-2 expression 
by immunoblotting. Both, Flip and Bcl-2 protein levels were downregulated in response to 
Cr(VI) exposure (Figs. 4, A and B). To determine whether these proteins are involved in the 
regulation of Cr(VI)-induced apoptosis, H460 cells were transiently transfected with Flip, 
Bcl-2 or control plasmid, and their effect on Cr(VI)-induced apoptosis was determined by 
Hoechst 33342 assay. Fig. 4C shows that transfection with both Flip and Bcl-2 inhibited 
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Cr(VI)-induced apoptosis as compared with the vector-transfected control, with the effect 
of Bcl-2 being more pronounced as compared to the effect of Flip. 
 
Bcl-2 Overexpression Protects Cells from Cr(VI)-Induced Apoptosis – To further verify the 
effect observed after transient transfection of Flip and Bcl-2 proteins. Stable H460 cell-
lines overexpressing Flip and Bcl-2 proteins were established and overexpression was 
confirmed by Western blot analysis. Transfected cells showed an increase in Bcl-2 and Flip 
protein expression in the Bcl-2-transfected cells and Flip-transfected cells but not in the 
control transfectant (Figs. 5, C and D). Further, stably transfected H460 cells with Flip, 
Bcl-2 or control plasmid, were tested for their effect on Cr(VI)-induced apoptosis by 
Hoechst 33342 assay. Overexpression of Bcl-2 significantly inhibited Cr(VI)-induced 
apoptosis over a wide concentration range as compared to the vector-transfected control 
(Fig. 5A), whereas Flip overexpression had minimal effect (Fig. 5B). These results indicate 
the role of Bcl-2 as a negative regulator of Cr(VI)-induced apoptosis and further suggest 
that H460 cells are Type II cells, supporting  the role of the mitochondrial pathway in 
Cr(VI)-induced cell death. 
 
Effect of Cr(VI) and ROS Modulators on Cellular ROS Levels – In the cellular system, 
Cr(VI) is metabolically reduced to its lower oxidation states, generating ROS in this 
process (14, 37, 38). Therefore, we quantified the induction of cellular ROS production in 
response to Cr(VI) exposure  by flow cytometry in treated cells using the fluorescent 
probes DCF and DHE, which detect hydroperoxide and ·O2‾, respectively. Cr(VI) induced 
hydroperoxide and ·O2‾ production in a dose-dependent manner, as indicated by the 
increase in DCF and DHE fluorescence intensity (Figs. 6, A-C). Various ROS modulators 
used in combination with Cr(VI) verified these results. DHE signal was increased by 
Cr(VI) and LY-83,583 (·O2‾ donor) and was inhibited by the addition of the SOD mimetic 
MnTBAP (·O2‾ scavenger) and the general antioxidant NAC (Fig. 7, A and F). Similarly, 
DCF signal was increased by Cr(VI) and H2O2 and was inhibited by NAC and catalase ( 
H2O2 scavenger) (Fig. 7, B and C).  
 
ROS Mediated Cr(VI) Induced Apoptosis – Apoptosis is strongly linked with ROS 
induction. To test whether the apoptosis-inducing effect of Cr(VI) is associated with ROS 
production, cells were treated with Cr(VI) in the presence or absence of various ROS 
modulators, including NAC, catalase, MnTBAP, and xanthine/xanthine oxidase (·O2‾ 
donor), and apoptosis was determined by Hoechst assay. The results show that all the tested 
antioxidants were able to inhibit apoptosis induced by Cr(VI) (Fig. 8, A and B), indicating 
that multiple ROS are involved in the apoptotic process. The potent inhibitory effects of 
catalase and MnTBAP further indicate that H2O2 and ·O2‾ play an important role in the 
process.  
 
GPx and SOD Overexpression Inhibits Cr(VI)-Induced Apoptosis and ROS Generation - 
To confirm the role of ROS in Cr(VI)-induced apoptosis, cells were stably transfected with 
the antioxidant enzymes GPx, SOD, or control plasmid, and their effects on ROS 
generation and apoptosis were determined. Apoptosis assays showed a decrease in 
apoptotic response to Cr(VI) treatment in GPx- and SOD-transfected cells but not in mock-
transfected cells (Fig. 9, A and B). Flow cytometric analysis of hydroperoxide generation 
and ·O2‾ also showed a substantial reduction in Cr(VI)-induced fluorescence in both GPx- 
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and SOD-transfected cells as compared with mock-transfected cells (Fig. 9, C and D). It 
was observed that SOD overexpressed cells showed more significant decrease in ROS and 
apoptosis induction. In SOD overexpressed cells, apoptosis did not change significantly 
even with 100 µM Cr(VI). This indicated significant involvement of ·O2‾ anion in Cr(VI)-
induced apoptosis.  
 
Mitochondrial ROS are Responsible for Cr(VI)-Induced Apoptosis – To determine the 
cellular source of ROS involved in Cr(VI)-induced apoptosis, cells were treated with 
Cr(VI) in the presence or absence of DPI, a specific inhibitor of NADPH oxidase (49, 50), 
or rotenone, a mitochondrial electron transport chain interrupter (50, 51), and their effects 
on apoptosis and ROS generation were examined. The results show that both DPI and 
rotenone inhibited Cr(VI)-induced ROS generation and apoptosis, with the effect of 
rotenone being more pronounced (Fig. 10, A-D). These results indicate that even though 
cytosolic ROS may be involved, mitochondria is the major source of ROS involved in 
Cr(VI)-induced apoptosis. The differential inhibitory effect of rotenone on ·O2‾ and 
peroxide generation could reflect the non-specific effect of this compound on ROS and the 
varying rates of reaction between the ROS, their probes, and the compound. The role of 
specific ROS in Cr(VI)-induced apoptosis could be more conclusively addressed using 
specific ROS modulators, as shown earlier. 
 
Cr(VI)-Induced ROS and Apoptosis is Reduced in H460 ρ0 Cells – Mitochondria is an 
important source of ROS that generates oxidative stress by incomplete reduction of oxygen 
from the electrons that escape normal oxidative phosphorylation (52). To confirm the role 
of mitochondrial ROS in Cr(VI)-induced apoptosis, we compared Cr(VI)-induced ROS 
formation in H460 and H460 ρ0 cells as assessed by DHE and DCF fluorescence. It was 
observed that Cr(VI)-induced ·O2‾ and ROS production in H460 cells was decreased 
significantly in H460 ρ0 cells (Figs. 11, A  and B). Further, it was observed that Cr(VI)-
induced apoptosis was reduced by half in H460 ρ0 cells as compared to H460 cells 
indicating that mitochondrial functional electron transport is important for mediating 
Cr(VI)-induced apoptosis (Fig. 11C).  
 
Effect of Cr(VI) on Bcl-2 Expression – To provide mechanistic insight into the regulation of 
Cr(VI)-induced apoptosis by Bcl-2, the expression level of Bcl-2 in response to Cr(VI) 
treatment was determined by Western blot analysis. Having demonstrated the role of Bcl-2 
in Cr(VI)-induced apoptosis, the effect of Cr(VI) treatment on Bcl-2 expression was 
characterized in these cells by immunoblotting.  Fig. 12A shows that treatment of the cells 
with Cr(VI) caused a dose-dependent decrease in the expression level of Bcl-2.  Fig. 12B 
shows that this effect of Cr(VI) was time-dependent with the effect clearly noticeable at 6 h 
post-treatment and thereafter.   
 
Effect of Antioxidants on Bcl-2 Expression – Having shown the role of Bcl-2 in Cr(VI)-
induced apoptosis, we next investigated the potential regulation of Bcl-2 by ROS. ROS 
have previously been shown to mediate tumor necrosis factor-induced proteasomal 
degradation of Bcl-2 in human umbilical vein endothelial cells (39). To test whether ROS 
might also mediate the effect of Cr(VI) on Bcl-2, cells were treated with Cr(VI) in the 
presence or absence of ROS modulators, and their effect on Bcl-2 expression was 
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determined. Figure 13A shows that treatment of the cells with MnTBAP completely 
inhibited Cr(VI)-induced Bcl-2 down-regulation, whereas catalase treatment showed no 
inhibitory effect suggesting an important role of ·O2‾ in Bcl-2 degradation. These results 
were confirmed in GPx- and SOD-overexpressed cells. Figure 13B shows that SOD 
overexpression completely inhibited Cr(VI)-induced Bcl-2 down-regulation, whereas GPx 
overexpression was ineffective. These results indicate that ·O2‾ is the primary ROS 
responsible for Cr(VI)-induced Bcl-2 down-regulation. Furthermore, the expression of Bcl-
2 was upregulated in H460 ρ0 cells suggesting that mitochondrial ·O2‾ is important in Bcl-2 
degradation (Fig. 13C). This is consistent with our earlier observation that mitochondrial 
·O2‾ is the major regulator of Cr(VI)-induced apoptosis. 
 
ROS Mediates Cr(VI)-Induced Ubiquitination of Bcl-2 - Previous studies have shown that 
Bcl-2 is down-regulated primarily through the proteasomal degradation pathway (39, 53), 
we tested whether such degradation is involved in the down-regulation of Bcl-2 by Cr(VI). 
Cells were treated with Cr(VI) in the presence or absence of lactacystin (LAC), a highly 
specific proteasome inhibitor, and its effect on Bcl-2 expression was determined. Figure 
14A shows that LAC completely inhibited Bcl-2 down-regulation induced by Cr(VI). This 
finding indicates that proteasomal degradation is a key mechanism of Cr(VI)-induced Bcl-2 
down-regulation. To further investigate the mechanism by which ROS mediates Cr(VI)-
induced Bcl-2 degradation, we analyzed ubiquitination of Bcl-2 in response to Cr(VI) 
treatment by immunoprecipitation. Cells overexpressing myc-Bcl-2 were treated with 
Cr(VI) in the presence or absence of ROS donors and inhibitors. Cell lysates were prepared 
and immunoprecipitated using anti-myc antibody. The resulting immune complexes were 
analyzed for ubiquitination by Western blot using anti-ubiquitin antibody. The results show 
that Cr(VI) was able to induce ubiquitination of Bcl-2 and the ·O2‾ donor LY-83,583 
increased this effect (Fig. 14B). In contrast, ·O2‾ scavenger MnTBAP inhibited Bcl-2 
ubiquitination, suggesting that ·O2‾ is the major ROS involved in Cr(VI) induced Bcl-2 
degradation. H2O2 donor and inhibitor had minimal effect. This result supported the pro-
apoptotic role of ROS in ubiquitin-mediated degradation of Bcl-2 by Cr(VI) and 



















Cr(VI) is a known human carcinogen that has been associated with lung cancer (3). Since 
acquired resistance to genotoxic cell death is a hallmark of neoplastic progression, it is 
important to understand the molecular mechanisms by which cells acquire an apoptosis 
resistant phenotype in response to genotoxic insult such as exposure to Cr(VI). Therefore, 
we first characterized the apoptotic pathways and regulatory proteins involved in Cr(VI)-
induced apoptosis. In this study, we demonstrated that Cr(VI) induces apoptosis in a dose 
dependent manner and zVAD completely blocked this effect (Fig.1). Since zVAD is a 
general caspase inhibitor, this result indicated that Cr(VI) induces apoptosis via classical 
caspase dependent manner. Apoptosis may be initiated through the stimulation of death 
receptors located on the cell surface or through the intrinsic pathway involving the release 
of apoptotic signals from mitochondria. To gain a mechanistic understanding of the 
susceptibility to cell death in response to Cr(VI) exposure, we further showed that both 
mitochondrial and death receptor pathways of apoptosis were activated by Cr(VI) (Fig. 2, A 
and B).  There have been studies suggesting a potential cross-talk between the two 
pathways in many cell-types. In the so called ‘Type I” cells, stimulation of death receptors 
has been reported to cause caspase-8 mediated cleavage and activation of caspase-3 (54, 
55). This pathway does not require mitochondria-associated events, whereas in “Type II’ 
cells caspase-8 leads to the cleavage and activation of Bid protein (56-58). Truncated bid 
stimulates formation of Bax pores in the outer mitochondrial membrane, which mediates 
the release of cytochrome c and, consequently, formation of Apaf-1/caspase-9 apoptosome 
(59). We observed that there is a potential cross-talk between the two apoptotic pathways in 
response to Cr(VI) exposure in H460 cells (Fig. 2C). Bid cleavage also suggested that 
H460 cells are Type II cells. Spectrofluorometric analysis further confirmed that both 
apoptotic pathways are induced by Cr(VI) exposure, with the mitochondrial pathway 
playing a more dominant role as compared to the death receptor pathway (Fig. 3, A and B). 
This observation was in agreement with another report that suggested that apoptotic doses 
of Cr(VI) caused mitochondrial instability (60). Various pro- and anti-apoptotic proteins 
regulate the extrinsic and intrinsic pathways. Interestingly, induction of pro-apoptotic 
proteins does not necessarily lead to apoptosis induction (26, 27), indicating that inhibitors 
of both apoptotic pathways exist and are important. Flip is the negative regulator of the 
death receptor pathway (25, 61, 62) while Bcl-2 plays a key role in the mitochondrial 
pathway (20, 28, 29). We observed that Cr(VI) downregulated both FLIP and Bcl-2 in a 
dose dependent manner (Fig. 4,  A and B). It was observed that Bcl-2 overexpression 
strongly blocked Cr(VI)-induced apoptosis, whereas Flip had minimal effect (Fig. 4C and 
5, A and C). This further substantiated the role of the mitochondrial death pathway in 
Cr(VI)-induced apoptosis.  
 
Cr(VI) is actively transported into cells by anionic transport system at the cellular level (64) 
and is metabolically changed to the ultimate reduced form, Cr(III), in a process that also 
produced ROS. Since generation of ROS is a definite consequence of Cr(VI) exposure we 
also demonstrated the role of ROS in Cr(VI)-induced apoptosis of human lung cancer 
epithelial H460 cells. Consistent with the observation that reduction of Cr(VI) inside the 
cell produces ROS, our results showed that Cr(VI) was able to induce ·O2‾ and peroxide 
generation in human lung epithelial H460 cells (Fig. 6 and 7). We also observed that ROS 
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was responsible for Cr(VI)-induced apoptosis (Fig. 8). This was verified in the presence of 
antioxidants such as NAC, catalase, and MnTBAP that effectively inhibited apoptosis 
induced by Cr(VI), indicating the role of ROS, specifically ·O2‾  and H2O2, in this process. 
H460 cells overexpressing GPx and SOD showed reduced apoptotic responses to Cr(VI) 
treatment (Fig. 9, A and B). This effect was more pronounced in SOD-overexpressed cells 
suggesting that even though both ·O2‾ and H2O2 are important, ·O2‾ is the major ROS 
involved in Cr(VI) apoptosis. To determine the source of ROS involved in Cr(VI)-induced 
apoptosis, we utilized DPI and rotenone. Rotenone has previously been shown to inhibit 
mitochondrial ROS and DPI is known to inhibit cellular NADPH oxidase and are 
considered as indicators of the mitochondrial and cytosolic ROS, respectively (49-51). 
Cr(VI) induced ROS generation and apoptosis was significantly inhibited by DPI and 
rotenone, with the effect of the latter being more dominant (Fig. 10). This indicated that 
total ROS produced in the cell is important in Cr(VI) induced apoptosis, but mitochondrial 
ROS plays a major role. This was further confirmed in H460 ρ0 cells which are prepared by 
long-term exposure to ethidium bromide that leads to the depletion of critical respiratory 
chain sub-units encoded by mitochondrial DNA (65, 66). Therefore these cells are 
incapable of generating mitochondrial ROS and normal oxidative phosphorylation (67). 
We observed decreased ROS production and apoptosis in H460 ρ0 as compared to H460 
cells (Fig. 11). Since ρ0 cells have dysfunctional mitochondria, this observation indicated 
an important role of mitochondrial electron transport chain and ROS in Cr(VI) induced 
apoptosis (68, 69). 
 
Since we observed that the anti-apoptotic protein Bcl-2 overexpression plays a key role in 
Cr(VI)-induced apoptosis, we tested the effect of Cr(VI) on Bcl-2 expression. Exposure of 
the cells to Cr(VI) caused a dose- and time-dependent down-regulation of Bcl-2 (Fig. 12, A 
and B). We found that this down-regulation was ROS dependent as co-treatment of the 
cells with the ·O2‾ scavenger MnTBAP completely inhibited the down-regulation of Bcl-2 
by Cr(VI) (Fig. 13A). H2O2 scavenger catalase failed to inhibit this effect, indicating that 
H2O2 has a minimal role in Cr(VI)-induced Bcl-2 down-regulation and apoptosis. Gene 
transfection studies using GPx- and SOD-overexpressed cells confirmed these results and 
indicated the critical role of ·O2‾ in this process (Fig. 13B). The observation that catalase 
and GPx failed to inhibit Bcl-2 down-regulation while exhibiting a protective effect on 
Cr(VI)-induced apoptosis suggests that other peroxide-mediated Bcl-2-independent 
mechanisms may be involved in the apoptotic effect of Cr(VI). It was further observed that 
H460 ρ0 cells inhibited Bcl-2 down-regulation when treated with Cr(VI) as compared to 
H460 cells(Fig. 13C). This suggested that mitochondrial ·O2‾ plays a critical role in 
maintaining Bcl-2 stability. The anti-apoptotic function of Bcl-2 is closely associated with 
its expression levels, which is controlled by various mechanisms. Post-translational 
modifications, such as ubiquitination and phosphorylation, have emerged as important 
regulators of Bcl-2 function (39, 40, 70). The ability of the proteasome inhibitor lactacystin 
to inhibit Bcl-2 down-regulation strongly supports the role of the proteasomal pathway in 
Bcl-2 regulation (Fig. 14A). We observed that ·O2‾ scavenger MnTBAP inhibited Bcl-2 
ubiquitination induced by Cr(VI), whereas ·O2‾ donor LY-83,583 promoted this effect (Fig. 
14B). H2O2 modulators had minimal effect. These results indicate that ·O2‾ downregulates 
Bcl-2 by inducing its degradation via the ubiquitin-proteasomal pathway in response to 
Cr(VI) exposure.  
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In summary, our data provides evidence that apoptosis induced by Cr(VI) is mediated 
through the mitochondrion-dependent caspase-9 activation pathway, which is negatively 
regulated by the anti-apoptotic Bcl-2 protein. ROS plays an important role in Cr(VI)-
induced apoptosis of human lung cancer epithelial H460 cells. The mechanism by which 
Cr(VI) induces apoptosis involves rapid generation of ROS and ·O2‾ is the major ROS 
involved. Mitochondria is the main source of ROS that is involved in Cr(VI)-induced 
apoptosis. Cr(VI) induces down-regulation of Bcl-2 through a process that involves ·O2‾-
mediated proteasomal degradation of the protein. Exposure to Cr(VI) is associated with 
lung cancer and Bcl-2 has been shown to be overexpressed in various cancers including 
lung tumor cells and tissue specimen (71-73). This aim established the importance of 
mitochondrial pathway and Bcl-2 protein in Cr(VI)-induced apoptosis which will further 
help in understanding the carcinogenicity of Cr(VI). ·O2‾ may represent a common 
regulator of Bcl-2 function that controls apoptotic cell death induced by various 
physiologic and pathologic stimuli. This study showing the role of ·O2‾ in Cr(VI)-induced 
cell death and Bcl-2 downregulation, documents a novel mechanism of apoptosis induction 
by Cr(VI) involving Bcl-2 stability linked to ·O2‾ generation. Signal transduction leading to 
apoptotic cell death has been of great interest in biomedical and pharmaceutical research 












































   
 














FIGURE 1. Induction of apoptosis by Cr(VI) in human lung epithelial H460 cells. A, 
subconfluent (90%) monolayers of H460 cells were exposed to varying doses of Cr(VI) (0-
100 µM) for 12 h, and the cells were analyzed for apoptosis by Hoechst 33342 assay. C, 
subconfluent (90%) monolayer of H460 cells were exposed to zVAD (25 µM) for 1 h and 
were then treated with Cr(VI) (20 µM) for 12 h, and the cells were analyzed for apoptosis 
by Hoechst 33342 assay. B and D, fluorescence micrographs of treated cells stained with 
Hoechst dye. Apoptotic cells exhibited shrunken and fragmented nuclei with bright nuclear 














































FIGURE 2. Signaling Cascades Induced by Cr(VI). H460 cells were treated with varying 
doses of Cr(VI) (10, 20, 50 µM) for 12 h, and cell lysates were prepared and analyzed for 








































FIGURE 3.  Caspase activation in response to Cr(VI) exposure. A, fluorometric assay of 
caspase activity in cells treated with varying doses of Cr(VI) (1-50 µM) for 12 h. Cell 
lysates (50 µg of protein) were prepared and analyzed for caspase activity using the 
fluorometric substrates IETD-AMC and LEHD-AMC for caspase-8 and -9, respectively. B, 
fluorometric assay of caspase activity in cells treated with Cr(VI) (20 µM) for 12 h in the 
presence or absence of the caspase-8 inhibitor IETD-CHO (10 µM) or caspase-9 inhibitor 
LEHD-CHO (10 µM). C, Apoptosis assay of caspase activity in cells treated with Cr(VI) 
(20 µM) for 12 h in the presence or absence of the caspase-8 inhibitor IETD-CHO (10 µM) 
or caspase-9 inhibitor LEHD-CHO (10 µM). Values are mean ± S.D. (n > 3). *, p < 0.05 
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FIGURE 4. Effect of Cr(VI) on apoptosis regulatory proteins. H460 cells were treated 
with varying doses of Cr(VI) (10, 20, 50 µM) for 12 h, and cell lysates were prepared and 
analyzed for A, Bcl-2 and B, Flip expression by Western blotting. Blots were reprobed with 
β-actin antibody to confirm equal loading of samples. C, H460 cells were transiently 
transfected with myc-tagged Bcl-2 plasmid, myc-tagged Flip plasmid or control pcDNA3 
plasmid. Transfected cells were treated with Cr(VI) (10 and 20 µM) for 12 h and apoptosis 






































FIGURE 5. Bcl-2 overexpression increases cell death resistance to Cr(VI). A and B, 
H460 cells were stably transfected with myc-tagged Bcl-2 plasmid, myc-tagged Flip 
plasmid or control pcDNA3 plasmid. Transfected cells were treated with varying doses of 
Cr(VI) (0-100 µM) for 12 h and apoptosis was determined by Hoechst 33342 assay. Plots 
are mean ± S.D. (n = 4). *, p < 0.05 versus mock-transfected controls. C, Western blot 
analysis of Bcl-2 expression in mock- and Bcl-2-transfected cells. D, Western blot analysis 
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FIGURE 6. Effect of Cr(VI) on cellular ROS levels. A, B and C, subconfluent (90%) 
monolayers of H460 cells were treated with varying doses of Cr(VI) (0-100 µM) and 













































FIGURE 7. Effect of ROS modulators on cellular ROS levels. A and B, subconfluent 
(90%) monolayers of H460 cells were pretreated with NAC (10 mM), MnTBAP (100 µM) 
or catalase (10000 U/ml) for 0.5 h, followed by Cr(VI) (20 µM) treatment. Plots show 
relative DHE or DCF fluorescence intensity over non-treated control determined at the 
peak response time of 1 h after Cr(VI) treatment. LY-83,583 (10 µM) and H2O2 (0.1 mM) 
were used as positive controls for DHE and DCF, respectively. C, Fluorescence 
micrographs of treated cells from above. Values are mean ± S.D. (n > 3). *, p < 0.05 versus 





































                                                                                                                                          
 
 
FIGURE 8. Induction of apoptosis by ROS modulators in H460 cells. A, subconfluent 
(90%) monolayers of H460 cells were either left untreated or pretreated with NAC (10 
mM), MnTBAP (100 µM), catalase (10000 U/ml) or xanthine/xanthine oxidase (1 mM/ 
0.02 U) for 1 h. The cells were then treated with Cr(VI) (20 µM) for 12 h and analyzed for 
apoptosis by Hoechst assay. B, Fluorescence micrographs of treated cells stained with 
















































FIGURE 9. Effect of GPx and SOD overexpression on Cr(VI)-induced apoptosis and 
ROS generation. A and B, H460 cells were stably transfected with GPx, SOD, or control 
pcDNA3 plasmid as described under Materials and Methods. Transfected cells were 
treated with Cr(VI) (1-100 µM) for 12 h and analyzed for apoptosis by Hoechst 33342 
assay. C and D, transfected cells were treated with Cr(VI) (1-100 µM) and analyzed for 
DCF and DHE fluorescence intensities at 1 h post-treatment. Plots show relative 




































FIGURE 10. Cellular source of Cr(VI)-induced ROS. A and B, Cells were pretreated for 
0.5 h with DPI (5 µM) or rotenone (5 µM), followed by Cr(VI) treatment (20 µM) and 
were analyzed for DHE and DCF fluorescence intensities at 1 h post-treatment. C, H460 
cells were either left untreated or pretreated with the indicated concentrations of DPI or 
rotenone for 1 h. Cells were then treated with Cr(VI) (20 µM) and analyzed for apoptosis 
after 12 h. D, fluorescence micrographs of treated cells stained with Hoechst 33342 dye. 











































FIGURE 11.  Cr(VI)-induced ROS and apoptosis is reduced in H460 ρ0 cells. A and B, 
H460 and H460 ρ0 cells were treated with Cr(VI) (10, 20 and 50 µM) for 1 h and analyzed 
for DHE and DCF fluorescence intensities. Plots show relative fluorescence intensity over 
non-treated control. C, subconfluent (90%) monolayers of H460 cells and H460 ρ0 cells 
were treated with varying doses of Cr(VI) (0-100 µM) for 12 h, and the cells were analyzed 











































FIGURE 12. Effect of Cr(VI) on Bcl-2 expression. A, H460 cells were treated with 
varying doses of Cr(VI) (0 - 100  µM) for 12 h, and cell lysates were prepared and analyzed 
for Bcl-2 expression by Western blotting. B, cells were treated for various times (0–24 h) 
with Cr(VI) (20 µM) and Bcl-2 expression was determined. Blots were reprobed with β-
actin antibody to confirm equal loading of samples. The immunoblot signals were 
quantified by densitometry, and mean data from independent experiments were normalized 
to the result obtained in cells in the absence of Cr(VI) (control). Plots are mean ± S.D. (n = 












































FIGURE 13. Effect of ROS modulators on Bcl-2 expression. A, H460 cells were either 
left untreated or pretreated with MnTBAP (100 µM), catalase (10000 U/ml), LY 83,583 
(10 µM) or H2O2 (0.1 mM) for 1 h, followed by Cr(VI) treatment (20 µM) for 12 h. Cell 
lysates were then prepared and analyzed for Bcl-2 expression by Western blotting. B, GPx-, 
SOD-, or mock-transfected cells were treated with Cr(VI) (10, 20 µM) for 12 h, and Bcl-2 
expression was determined by Western blotting. C, H460 and H460 ρ0 cells were treated 
with Cr(VI) (10, 20 µM) for 12 h, and Bcl-2 expression was similarly determined. Blots 
were reprobed with β-actin antibody to confirm equal loading of samples. Densitometry 
was performed to determine the relative expression of Bcl-2 in treated cells compared with 


































FIGURE 14. Effect of ROS on Bcl-2 ubiquitination. A, H460 cells were either left 
untreated or pretreated with LAC (10 µM) for 0.5 h, followed by Cr(VI) treatment (20 µM) 
for 12 h. Cell lysates were then prepared and analyzed for Bcl-2 expression by Western 
blotting. B, subconfluent monolayers of H460 cells overexpressing Bcl-2 were pretreated 
with MnTBAP (100 µM), catalase (10000 U/ml), LY-83,583 (10 µM ) and H2O2 (0.5 mM) 
for 1 h. Subsequently, the cells were treated with Cr(VI) (20 µM) for 3 h in the presence of 
LAC (10 µM) to prevent proteasome-mediated Bcl-2 degradation. Cell lysates were 
immunoprecipitated with anti-myc antibody and the immune complexes were analyzed for 
ubiquitin by Western blotting. Analysis of ubiquitin was performed at 3 h post-Cr(VI) 
treatment where ubiquitination was found to be maximal. Plots are mean ± S.D. (n = 4). *, 
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Bcl-2 is a key apoptosis regulatory protein of the mitochondrial death pathway whose 
function is dependent on its expression levels. Although Bcl-2 expression is controlled by 
various mechanisms, post-translational modifications, such as ubiquitination and 
proteasomal degradation, have emerged as important regulators of Bcl-2 function. 
However, the underlying mechanisms of this regulation are unclear. We report here that 
Bcl-2 undergoes S-nitrosylation by endogenous nitric oxide (NO) in response to multiple 
apoptotic mediators and that this modification inhibits ubiquitin-proteasomal degradation 
of Bcl-2. Inhibition of NO production by the NO scavenger 2-(4-carboxyphenyl)-4,4,5,5-
tetramethylimidazoline-1-oxyl-3-oxide and by NO synthase inhibitor aminoguanidine 
effectively inhibited S-nitrosylation of Bcl-2, increased its ubiquitination, and promoted 
apoptotic cell death induced by Cr(VI). In contrast, NO donors dipropylenetriamine 
NONOate and sodium nitroprusside showed opposite effects. Furthermore, it was observed 
that NO scavenged ·O2‾ forming peroxynitrite, which was the major reactive nitrogen 
species involved in S-nitrosylation of Bcl-2. The effect of NO on Bcl-2 stability was shown 
to be independent of its dephosphorylation. Mutational analysis of Bcl-2 further showed 
that the two cysteine residues of Bcl-2 (Cys158 and Cys229) are important in the S-
nitrosylation process and that mutations of these cysteines completely inhibited Bcl-2 S-
nitrosylation. Treatment of the cells with other stress inducers, including Fas ligand and 
buthionine sulfoxide, also induced Bcl-2 S-nitrosylation, suggesting that this is a general 
phenomenon that regulates Bcl-2 stability and function under various stress conditions. 
These findings indicate a novel function of NO and its regulation of Bcl-2, which provides 


























Bcl-2 is a key apoptosis-regulatory protein of the mitochondrial death pathway(1). 
Formation of heterodimers with proapoptotic proteins such as Bax, inhibition of 
cytochrome c release, and regulation of mitochondrial transmembrane potential are some of 
the mechanisms by which Bcl-2 exerts its antiapoptotic effect (2-4). The oncogenic 
potential of Bcl-2 protein is well characterized. It is overexpressed in 70% of breast cancer, 
30–60% of prostate cancer, and 90% of colorectal cancer (5, 6). Additionally, its 
expression has been reported to be amplified in several apoptosis-resistant lung cell lines 
and tumor specimens (7-9). Bcl-2 expression is regulated by various mechanisms, 
including dimerization, post-translational modification, transcription, and degradation. Bcl-
2 degradation is mainly mediated via the ubiquitin-proteasomal pathway, which is a major 
system for selective protein degradation in eukaryotic cells (10, 11). Nitric oxide (NO) is an 
important signaling molecule produced endogenously from L-arginine in a reaction 
catalyzed by NO synthases (12). Subtle changes in its rate of production may critically 
impact cellular homeostasis, consequently initiating a variety of cellular signaling 
processes, including apoptosis (13). NO has been demonstrated to have both pro- and anti-
apoptotic role, depending on a variety of factors, including the type of cells involved, redox 
state of the cell, and the flux and dose of NO (12). Recent evidence indicates that NO 
activates a complex network of responses leading to apoptosis via mitochondrial, death 
receptor, p38/mitogen-activated protein kinase, and glyceraldehyde-3-phosphate 
dehydrogenase-Siah1 cascades (14-17). The anti-apoptotic effect of NO can be mediated 
through a number of mechanisms, such as caspase inactivation, induction of p53 gene 
expression, up-regulation of FLIP, and overexpression of Bcl-2 and Bcl-XL with 
subsequent inhibition of cytochrome c release from the mitochondria (18-24). NO freely 
diffuses across cell membranes and interacts with many other molecules. For instance, it 
reacts rapidly with ·O2‾ anions in a diffusion controlled reaction to primarily form 
peroxynitrite (ONOO¯) in most cell systems (25). The effects of ONOO- on protein 
function are mainly due to its reactivity and covalent modification of tyrosine and/or 
cysteine residues (26). One of the well-established mechanisms by which NO through the 
formation of ONOO¯ regulates the function of various target proteins is via S-nitrosylation 
(27). This post-translational modification of proteins can positively or negatively regulate 
various signaling pathways, proteins, and metabolic processes (28). For instance, NO 
inhibits the function of NF-κB, JNK and protein kinase C and activates Ras and ryanodine 
receptor via S-nitrosylation (29-33). Even though NO has been widely implicated in 
apoptosis and its dysregulation, its role in cancer is not well characterized. The 
involvement and the role of NO in Cr(VI)-induced apoptosis has never been studied.  
 
The objective of this study was to investigate the role of NO in the regulation of Bcl-2 
function in Cr(VI)-induced apoptosis of human lung epithelial cancer cells. Cr(VI) is a 
naturally occurring heavy metal that has been associated with lung cancers in various 
occupational settings (35-38). This compound is also present in cigarette smoke, and an 
increased incidence of lung cancer has been reported in smokers with Cr(VI) exposure (34, 
36). Cell death induced by Cr(VI) occurs primarily through apoptosis (39), and its 
abnormal regulation has been associated with the initiation of Cr(VI)-induced cancer (40). 
Several cellular factors and signaling pathways, such as reactive oxygen species, p53, and 
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NF-κB activation have been implicated in Cr(VI)-induced apoptosis and carcinogenicity 
(41-43). However, the mechanisms involved in the abnormal regulation of apoptosis in 
response to Cr(VI) exposure remain unclear. Elevated levels of Bcl-2 and NO production 
have been reported in human lung cancers (7-9, 44-46). In the present study, we found that 
NO up-regulates Bcl-2 expression, which provides a key mechanism against Cr(VI)-
induced apoptosis. The mechanism by which NO regulates Bcl-2 involves S-nitrosylation 
of the protein, which was also observed under other stress conditions, including exposure to 
death ligand and glutathione depletion. ONOO¯ is the major reactive nitrogen species 
involved in S-Nitrosylation of Bcl-2 that prevents its downregulation via the ubiquitin-
proteasome pathway. Mutational analysis indicated the involvement of Cys158 and Cys229 in 
S-nitrosylation and ubiquitination of Bcl-2. These findings reveal the existence of a novel 
mechanism of NO-mediated regulation of Bcl-2 that could be important in apoptosis 



































3.3. Materials and Methods 
 
Cells and Reagents 
The human lung epithelial cancer cell line NCI-H460 was obtained from the American 
Type Culture Collection (Rockville, MD). Cells were cultured in RPMI 1640 medium 
(Sigma) containing 5% fetal bovine serum, 2mM L-glutamine, 100 units/ml penicillin, and 
100 µg/ml streptomycin in a 5% CO2 environment at 37°C. The NO donor sodium 
nitroprusside (SNP), NO inhibitors aminoguanidine (AG) and 2-(4-carboxyphenyl)-4,4,5,5-
tetramethyl-imidazoline-1-oxy-3-oxide (PTIO), lactacystin, buthionine sulfoximine (BSO), 
dithiothreitol (DTT), diaminonaphthalene (DAN), mercury (II) chloride (HgCl2), sodium 
hydroxide (NaOH), sulfonilamide, N-1-naphthyl ethylenediamine dehydrochloride, sodium 
nitrite (NaNO2), 6-Anilinoquinoline-5,8-quinone (LY-83,583) and sodium dichromate 
(Na2Cr2O7.2H2O) [(Cr(VI)] were obtained from Sigma (St. Louis, MO). The NO donor 
dipropylenetriamine (DPTA) NONOate, Fas ligand (FasL) and the fluorogenic caspase 
substrates IETD amino-4-methylcoumarin (IETD-AMC) and LEHD-AMC were from 
Alexis Biochemicals (San Diego, CA). Mn(III)tetrakis (4-benzoic acid) porphyrin 
(MnTBAP) was purchased from Calbiochem (La Jolla, CA). The NO fluorescent probe 
4,5-diaminofluorescein diacetate (DAF-DA), DHE and the apoptosis dye Hoechst 33342 
were from Molecular Probes, Inc. (Eugene, OR). Antibodies for Bcl-2, phospho-Bcl-2 
(Ser87), Myc, peroxidase-labeled secondary antibodies, anti-myc agarose beads, and 
protein A-agarose were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibodies 
for S-nitrosocysteine, ubiquitin, and β-actin were from Sigma, and the transfecting agent 
Lipofectamine 2000 was from Invitrogen (Carlsbad, CA). 
 
Plasmid and Transfection 
The Bcl-2 plasmid was generously provided by Dr. Christian Stehlik (West Virginia 
University Cancer Center, Morgantown, WV). The open reading frame of Bcl-2 and 
ubiquitin were amplified by high fidelity PCR (Stratagene, La Jolla, CA) from 
corresponding expressed sequence tags and cloned into pcDNA3 expression vectors 
containing N-terminal myc epitope tag. The authenticity of all constructs was verified by 
DNA sequencing. Transient transfection was performed using Lipofectamine 2000 reagent 
according to the manufacturer’s instructions. The amount of DNA was normalized in all 
transfection experiments with pcDNA3. Expression of proteins were verified by Western 
blotting or immunoprecipitation. 
 
Generation of Stable Bcl-2 Transfectant 
Stable transfectant of Bcl-2 was generated by culturing H460 cells in 60-mm dishes until 
they reached 80% confluence. 1 µg of cytomegalovirus-neo vector and 15 µl of 
Lipofectamine 2000 with 2 µg of myc-tagged Bcl-2 plasmid were used to transfect the cells 
in the absence of serum. After 10 h, the medium was replaced with culture medium 
containing 5% fetal bovine serum. Approximately 36 h after transfection, the cells were 
digested with 0.03% trypsin and plated onto 75-ml culture flasks and cultured for 24–28 
days with G418 selection medium (400 µg/ml). The stable transfectant was identified by 
Western blotting of Bcl-2 and was cultured in G418-free RPMI medium for at least two 
passages before each experiment. 
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Caspase and Apoptosis Assays 
Caspase activity was determined by fluorometric assay using the enzyme substrate IETD-
AMC for caspase-8 and LEHD-AMC for caspase-9, which are specifically cleaved by the 
respective enzymes at the Asp residue to release the fluorescent group, AMC. Cell extracts 
containing 50 µg of protein were incubated with 100 mM HEPES containing 10% sucrose, 
10 mM dithiothreitol, 0.1% 3-((3-cholamidiopropyl)-1) propane sulfonate, and 50 µM 
caspase substrate in a total reaction volume of 0.25 ml. The reaction mixture was incubated 
for 60 min at 37°C and quantified fluorometrically at the excitation and emission 
wavelengths of 380 and 460 nm, respectively. Apoptosis was determined by incubating the 
cells with 10 µg/ml Hoechst 33342 nuclear stain for 30 min at 37°C and scoring the 
percentage of cells having intensely condensed chromatin and/or fragmented nuclei by 
fluorescence microscopy (Axiovert 100; Carl Zeiss) using Pixera software. 
 
NO Detection 
Intracellular NO production was determined by flow cytometry and fluorescence 
microscopy using NO-specific probe DAF-DA. For flow cytometric analysis, cells (1 x 
106/ml) were incubated with the probe (10 µM) for 30 min at 37°C, after which they were 
washed, resuspended in phosphate-buffered saline (PBS), and analyzed for DAF 
fluorescence intensity using a 488-nm excitation beam and a 538-nm bandpass filter 
(FACS calibur; Becton-Dickinson). For fluorescence microscopy, cells were incubated 
with the probe as described above and then examined for DAF fluorescence using Carl 
Zeiss Axiovert microscope.  
 
Griess Assay 
NO production was confirmed by measuring its nitrite by-product using Griess assay. Cell 
supernatants (50 µl) were incubated with 50 µl of Griess reagent containing 0.1% N-1-
naphthyl ethylenediamine dehydrochloride and 1% sulfanilamide for 10 min at room 
temperature. The optical density of the samples was measured using a microplate reader 
(model 550; Bio-Rad) at 550 nm. NO concentration was calculated from the standard curve 
produced during each assay by using NaNO2 dissolved in 15 mM HEPES, pH 7.5. 
 
Western Blotting 
After specific treatments, cells were incubated in lysis buffer containing 20 mM Tris-HCl 
(pH 7.5), 1% Triton X-100, 150 mM NaCl, 10% glycerol, 1 mM Na3VO4, 50 mM NaF, 
100 mM PMSF, and protease inhibitor mixture for 20 min on ice. After insoluble debris 
was precipitated by centrifugation at 14,000 x g for 15 min at 4°C, the supernatants were 
collected and assayed for protein content using BCA method. An equal amount of proteins 
per sample (15 µg) were resolved on 10% SDS-PAGE and transferred onto a 0.45-µm 
nitrocellulose membrane. The transferred membranes were blocked for 1 h in 5% non-fat 
dry milk in TBST (25 mM Tris-HCl, pH 7.4, 125 mM NaCl, 0.05% Tween 20) and 
incubated with the appropriate primary antibodies and horseradish peroxidase-conjugated 
secondary antibodies. The immune complexes were detected by chemiluminescence 
(Supersignal West Pico; Pierce) and quantified by imaging densitometry using UN-SCAN-
IT automated digitizing software (Silk Scientific, Orem, UT). Mean densitometry data from 
independent experiments were normalized to the control. The data were presented as mean 




Cells were washed after treatments with ice-cold PBS and lysed in lysis buffer at 4°C for 
20 min. After centrifugation at 14,000 x g for 15 min at 4°C, the supernatants were 
collected, and the protein content was determined as described. Cleared lysates were 
normalized, and 60 µg of proteins were incubated with 8 µl of anti-myc-agarose beads 
(Santa Cruz Biotechnology) diluted with 12 µl of protein A-agarose for 4 h at 4°C. The 
immune complexes were washed three times with 500 µl of lysis buffer, resuspended in 2 x 
Laemmli sample buffer, and boiled at 95°C for 5 min. The immune complexes were 
separated by 10% SDS-PAGE and analyzed by Western blot as described. 
 
Fluorometric Measurement of S-Nitrosylation 
S-Nitrosylation of Bcl-2 was measured as previously described (31, 47). In brief, cells were 
treated, harvested, lysed, and subjected to immunoprecipitation. The immunoprecipitates 
were rinsed four times with lysis buffer and twice with PBS. The pellets were resuspended 
in 500 µl of PBS and incubated with HgCl2 (200 µM) and diaminonaphthalene (DAN) 
(200 µM) for 0.5 h in dark at room temperature followed by the addition of 1 M NaOH. A 
fluorescent triazole generated from the reaction between DAN and NO released from S-
nitrosylated Bcl-2 was quantified using a fluorometer (FLUOstar OPTIMA, BMG Inc., 
Durham, NC) at the excitation and emission wavelengths of 375 and 450 nm, respectively. 
 
Site-directed Mutagenesis of Bcl-2 
Mutant Bcl-2 plasmids were constructed using the above-mentioned human Bcl-2 plasmid 
as template. Two sets of forward and reverse primers were constructed to introduce 
mutations at Cys158 and Cys229: C158A, CGGTGGGGTCATGGCTGTGGA 
GAGCGTCAACCG (forward) and CGGTTGACGCTCTCCACAGCCATGACCCCAG  
(reverse); C229A, GGCCCTGGTGGGAGCTGCCATCACCCTGGGTGCC (forward) and 
GGCACCCAGGGTGATGGCAGCTCCCACCAGGGCC (reverse). Three mutant 
plasmids (C158A, C229A, and a plasmid with both mutations) were constructed using the 
QuikChange XL site-directed mutagenesis kit (Stratagene). Mutagenesis was confirmed by 
automated nucleotide sequencing. 
 
Proteasome Activity Assay 
Proteasome activity was measured using an assay kit from CHEMICON (Temecula, CA), 
according to the manufacturer’s protocol. Briefly, cells were washed after treatments with 
ice-cold PBS and lysed in lysis buffer at 4°C for 20 min. After centrifugation at 14,000 x g 
for 15 min at 4 °C, the supernatants were collected and protein content was determined by 
BCA method. Cleared lysates were normalized, and 20 µg of proteins were incubated with 
the proteasome substrate LLVY-AMC at 37°C for 1 h. The fluorophore AMC obtained 
after cleavage from the labeled substrate was quantified at the excitation and emission 
wavelengths of 380 and 460 nm, respectively.  
 
ROS Detection 
Intracellular ·O2‾ production was determined by spectrofluorometry using DHE  as the 
fluorescence probe. Cells (1x106/ml) were incubated with the fluoresecent probe (10 µM) 
for 30 min at 37ºC, after which they were washed, resuspended in phosphate buffered 
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saline (PBS), and analyzed for DHE fluorescence at the excitation and emission 
















































NO Inhibits Cr(VI)-induced Apoptosis – As shown in the previous aim, Cr(VI) induces 
apoptosis in a dose-dependent manner mainly via the mitochondrial pathway. To 
investigate the potential role of NO in the regulation of Cr(VI)-induced apoptosis, cells 
were treated with Cr(VI) in the presence or absence of various NO inhibitors and donors, 
and apoptosis was determined by Hoechst assay. Figs. 1, A and B, show that NO inhibitors 
AG and PTIO effectively increased apoptotic cell death induced by Cr(VI), whereas NO 
donors SNP and DPTA NONOate inhibited this effect in a dose-dependent manner. 
Caspase activity assays similarly showed that the NO inhibitor AG and the NO donor SNP, 
respectively, increased and decreased the effect of Cr(VI) on capase-9 activation (Fig. 1C). 
These results indicate that NO plays an anti-apoptotic role in Cr(VI)-induced apoptosis. 
 
Effect of NO Modulators on Cellular NO Level - To provide a relationship between the 
apoptotic response and NO modulation by the test agents, we performed flow cytometric 
analysis assessing the effect of test agents on cellular NO production using the fluorescent 
probe DAF DA. Fig. 2, A and B, show that the NO inhibitors AG and PTIO significantly 
inhibited cellular NO production induced by Cr(VI), whereas the NO donors SNP and 
DPTA NONOate promoted this effect. Fig. 2C shows fluorescence micrographs of cells 
treated with Cr(VI) in the presence or absence of NO modulators. Since Cr(VI) exposure is 
known to produce ROS (39, 40) and due to the report challenging the specificity of DAF 
DA to NO in cells undergoing oxidative and nitrosative stress (50), we confirmed this 
effect by the Griess method. Griess assay measures nitrite, which is the stable breakdown 
product of NO. Fig. 2D shows that NO inhibitors inhibited cellular nitrite production 
induced by Cr(VI), whereas the NO donors SNP and DPTA NONOate increased its levels. 
These results indicate the modulation of cellular NO levels by the test agents and support 
the role of NO in the regulation of Cr(VI)-induced apoptosis. 
 
Effect of NO Modulators on Bcl-2 Expression – Having demonstrated the role of Bcl-2 in 
Cr(VI)-induced apoptosis in the previous aims, we next examined the potential regulation 
of Bcl-2 by NO in H460 cells. We treated the cells with Cr(VI) in the presence or absence 
of various NO modulators, including AG, PTIO, SNP, and DPTA NONOate, and the 
expression level of Bcl-2 was similarly determined. Fig. 3A shows that the NO inhibitors 
AG and PTIO significantly increased the down-regulation of Bcl-2 by Cr(VI), whereas the 
NO donors SNP and NONOate inhibited this down-regulation and further increased the 
Bcl-2 expression level over control level. Fig. 3B shows the effect of AG and PTIO alone 
as controls on Bcl-2 expression. Since previous studies have shown that Bcl-2 is rapidly 
down-regulated by proteasomal degradation (10), we tested whether Bcl-2 down-regulation 
by Cr(VI) is also mediated by this pathway. Cells were treated with lactacystin, a highly 
specific proteasome inhibitor, and its effect on Cr(VI)-induced Bcl-2 down-regulation was 
determined by immunoblotting. The result in Fig. 3A shows that lactacystin completely 
inhibited Bcl-2 down-regulation induced by Cr(VI), indicating a dominant role of 
proteasome-mediated degradation of Bcl-2 by Cr(VI).  
 
Effect of NO on Bcl-2 Phosphorylation - Accumulating evidence indicates that Bcl-2 
phosphorylation induces a conformational change in Bcl-2 that controls its stability and 
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apoptotic function (51-53). Phosphorylation of Bcl-2 at Thr 74 and Ser 87 has been shown 
to regulate its stability and dephosphorylation at Ser 87 is the initial step of Bcl-2 
degradation (10, 54). Since our results demonstrated that NO can prevent Bcl-2 
degradation, we further investigated the effect of NO on Bcl-2 phosphorylation. Cells were 
treated with Cr(VI) in the presence or absence of various NO modulators, and their effect 
on Bcl-2 phosphorylation was determined by Western blot using phosphospecific Bcl-2 
(Ser 87) antibody. The results show that Cr(VI) had minimal effect on Bcl-2 
phosphorylation, and likewise NO donors and inhibitors had no significant effect on the 
phosphorylation level (Fig. 3C). These results suggest that NO regulates Bcl-2 stability via 
a mechanism that is independent of its phosphorylation. 
 
NO Prevents Cr(VI)-induced Ubiquitination of Bcl-2 - To further investigate the 
mechanism by which NO inhibits Cr(VI)-induced Bcl-2 degradation, we analyzed 
ubiquitination of Bcl-2 in response to Cr(VI) treatment by immunoprecipitation. Cells 
overexpressing myc-Bcl-2 were treated with Cr(VI) in the presence or absence of NO 
donors and inhibitors. Cell lysates were prepared and immunoprecipitated using anti-myc 
antibody. The resulting immune complexes were analyzed for ubiquitination by Western 
blot using anti-ubiquitin antibody. The results show that Cr(VI) was able to induce 
ubiquitination of Bcl-2 and that NO inhibitors AG and PTIO increased this effect (Fig. 4). 
In contrast, NO donors SNP and DPTA NONOate inhibited Bcl-2 ubiquitination, thus 
supporting the inhibitory role of NO in ubiquitin-mediated degradation of Bcl-2 by Cr(VI). 
 
NO-mediated S-Nitrosylation of Bcl-2 Inhibits its Ubiquitination - NO can control the 
function of several proteins by S-nitrosylation process (55-57). To determine whether NO 
could nitrosylate Bcl-2 and whether this process could affect Bcl-2 stability, we performed 
immunoprecipitation experiments evaluating the effect of NO on Bcl-2 S-nitrosylation. 
Cells expressing ectopic Bcl-2-myc were treated with Cr(VI) and NO modulators, and cell 
lysates were immunoprecipitated and analyzed by Western blot analysis using anti-S-
nitrosocysteine antibody and by spectrofluorometry. Figs. 5, A and B, show that treatment 
of the cells with Cr(VI) induced S-nitrosylation of Bcl-2, and this effect was enhanced by 
NO donors SNP and DPTA NONOate. In contrast, NO inhibitors AG and PTIO inhibited 
this nitrosylation process. These results suggest that NO, through its ability to nitrosylate 
Bcl-2, may interfere with the ubiquitination process and inhibit Bcl-2 degradation by the 
proteasome. To test this possibility, we treated cells with a known inhibitor of S-
nitrosylation, DTT (58, 59), and its effects on Bcl-2 S-nitrosylation and ubiquitination were 
determined. The results show that DTT was able to prevent S-nitrosylation of Bcl-2 (Fig. 
5A). Furthermore, it negated the effect of NO donors SNP and DPTA NONOate on Bcl-2 
ubiquitination in Cr(VI)-treated cells (Fig. 5C). These results indicate that S-nitrosylation 
might be a key mechanism utilized by NO to regulate ubiquitination and degradation of 
Bcl-2 by the proteasome. Recent reports suggest that NO could directly regulate 
proteasome activity by S-nitrosylation of E3 ubiquitin ligases (parkin, Mdm2) (60, 61). To 
confirm that the effect observed on Bcl-2 ubiquitination is specifically due to its S-
nitrosylation, we treated cells with DTT in the presence and absence of Cr(VI) and 
determined its effects on proteasome activity. Cells expressing ectopic Bcl-2-myc were 
treated with Cr(VI) and DTT, and cell lysates were immunoprecipitated and analyzed for 
proteasome activity by spectrofluorometry. The results show that DTT had no significant 
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effect on proteasomal activity as compared with Cr(VI) treatment alone (Fig. 5D), 
confirming that this effect is specifically due to modification and S-nitrosylation of Bcl-2. 
 
S-Nitrosylation of Bcl-2 under Other Stress Conditions - To determine whether S-
nitrosylation of Bcl-2 was a general phenomenon, we performed immunoprecipitation 
experiments evaluating the effect of other stress inducers including FasL and BSO on Bcl-2 
S-nitrosylation. The results show that these test agents also induced S-nitrosylation of Bcl-2 
(Figs. 6, A and B), suggesting that this process is a general phenomenon that regulates the 
anti-apoptotic function of Bcl-2. 
 
Mutations at Cys158 and Cys229 Prevents Bcl-2 S-Nitrosylation - To confirm Bcl-2 S-
nitrosylation and to determine the cysteine residue(s) that may be involved in the process, 
we constructed Bcl-2 mutant plasmids replacing the two cysteines in Bcl-2 with alanines. 
The mutant plasmids and the original Bcl-2 plasmid were individually introduced into 
H460 cells by transient transfection. Transfected cells were treated with Cr(VI), and cell 
lysates were prepared and analyzed for S-nitrosylated Bcl-2 by Western blotting using anti-
S-nitrosocysteine antibody. The results show that treatment of the cells with Cr(VI) induced 
S-nitrosylation of Bcl-2, which was completely inhibited by one or both cysteine mutations 
(Fig. 7, A and B). The results also show that although both cysteines undergo S-
nitrosylation in response to Cr(VI) treatment, Cys229 is the major site of Bcl-2 nitrosylation. 
To test whether S-nitrosylation of Bcl-2 could stabilize the protein and prevent its 
degradation, we tested the effect of mutant plasmids on Bcl-2 ubiquitination. Cells were 
transfected with the plasmids and treated with Cr(VI) as described. Cell lysates were 
immunoprecipitated and analyzed by Western blot using anti-ubiquitin antibody. The 
results show that cysteine mutations led to increased ubiquitination of Bcl-2 by Cr(VI) (Fig. 
8A), indicating that S-nitrosylation of the protein prevents its ubiquitination and subsequent 
degradation. We also observed that transient transfection with the mutant plasmids 
increased apoptotic response to Cr(VI) exposure as compared to the wild-type plasmid 
(Fig. 8B). Increased apoptosis was observed in cells transfected with Cys229 mutant plasmid 
as compared to cells transfected with Cys158 mutant plasmid confirming that Cys229 is the 
major site of Bcl-2 nitrosylation. This observation indicates that S-nitrosylation of Bcl-2 
stabilizes the protein and maintains its anti-apoptotic function.  
 
NO Reacts with ·O2‾ to Form ONOO¯ that Causes S-nitrosylation of Bcl-2 – We 
demonstrate that NO plays an anti-apoptotic role in Cr(VI)-induced apoptosis by stabilizing 
Bcl-2 protein via S-nitrosylation. However, recent evidences suggest that ONOO¯ is the 
major nitrogen species involved in S-nitrosylation, specifically in systems with increased 
·O2‾ production. As shown in the previous aim, ·O2‾ mediates Cr(VI)-induced apoptosis by 
the down-regulation of Bcl-2 protein, we therefore tested the possibility of the involvement 
of ONOO¯ in Bcl-2 nitrosylation in response to Cr(VI) exposure. H460 cells were treated 
with ·O2‾ modulators in addition to Cr(VI) and were assessed for NO levels by 
spectrofluorometry. Similarly, we treated cells with NO modulators and tested the effect on 
·O2‾ level. We observed increased NO levels in cells treated with ·O2‾ inhibitor (MnTBAP) 
and decreased levels in cells treated with ·O2‾ donor (LY-83,583) (Fig. 9A). Similarly, 
treatment with NO donors decreased ·O2‾ levels whereas NO inhibitors increased ·O2‾ 
levels (Fig. 9B). This suggested a direct correlation between NO and ·O2‾ levels and 
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indicated that NO may be scavenging ·O2‾ forming ONOO¯ in response to Cr(VI) 
exposure. We also found that ONOO¯ donor (SIN1) had a protective effect in Cr(VI) 
induced apoptosis (Fig. 10, A and B). Furthermore, ·O2‾ modulators affected S-nitrosylation 
with donors showing increased effect and inhibitors completely blocking the effect (Fig. 10 
C). These results suggest that ONOO¯ formation in response to Cr(VI) treatment leads to 













































Many cell-based studies have demonstrated that overexpression of Bcl-2 increases 
resistance to apoptotic cell death induced by various DNA-damaging agents, which is an 
important feature of malignant cells (7-9). Similarly, NO has been shown to be elevated in 
many cancer cells (44-46); however, its potential role in the regulation of Bcl-2 and the 
underlying mechanisms has not been demonstrated. In the present study, we show that NO, 
through the formation of ONOO¯ regulates Bcl-2 protein via S-nitrosylation and that this 
mechanism stabilizes the protein, maintaining its anti-apoptotic function. In the previous 
aims, we have established that ROS, specifically ·O2‾, mediates Cr(VI)-induced apoptosis 
via the mitochondrial death pathway. Further, we showed that Bcl-2 overexpression 
inhibited Cr(VI)-induced apoptosis and ROS mediated its effect by down-regulation of 
Bcl-2. In this study, we observed that the addition of NO donors SNP and DPTA NONOate 
effectively inhibited this down-regulation and decreased cell death (Figs. 1 and 3). In 
contrast, NO inhibitors AG and PTIO showed opposite effects, indicating the anti-apoptotic 
role of NO and its regulation of Bcl-2 in the test system. It has been reported that apoptotic 
doses of Cr(VI) caused mitochondrial instability (62). The anti-apoptotic function of Bcl-2 
is closely associated with its expression levels. Although Bcl-2 expression is controlled by 
various mechanisms, post-translational modifications, such as ubiquitination and 
phosphorylation, have emerged as important regulators of Bcl-2 function (7, 8). Our results 
show that down-regulation of Bcl-2 by Cr(VI) was associated with an increase in Bcl-2 
ubiquitination and proteasomal degradation (Figs. 4 and 5). The ability of the proteasome 
inhibitor lactacystin to inhibit Bcl-2 down-regulation strongly supports the role of the 
proteasomal pathway in Bcl-2 regulation. The NO donors SNP and DPTA NONOate 
inhibited Bcl-2 ubiquitination by Cr(VI), whereas the NO inhibitors AG and PTIO 
promoted this effect (Fig. 4). These results indicate that NO regulates Bcl-2 stability by 
preventing its degradation via the ubiquitin-proteasomal pathway. It has been reported that 
Bcl-2 stability is regulated by phosphorylation at Thr 74 and Ser 87 and dephosphorylation 
at Ser 87 in response to proapoptotic stimuli, such as TNF-α, is the initial step of Bcl-2 
degradation (10). Since NO prevented down-regulation of Bcl-2 in our system, we studied 
the effect of NO on Bcl-2 phosphorylation. However, we found that NO had no significant 
effect on Bcl-2 phosphorylation (Fig. 3), indicating that NO may regulate Bcl-2 stability 
through a mechanism that does not require Bcl-2 dephosphorylation. TNF-α is a death 
ligand that induces apoptosis via the death receptor pathway, whereas Cr(VI) induces cell 
death primarily via the mitochondrial pathway. Therefore, its mechanism of Bcl-2 
regulation may be different from Cr(VI). Our results suggest that dephosphorylation of Bcl-
2 might not be a necessary event for triggering Bcl-2 ubiquitination and that different 
mechanisms of Bcl-2 regulation exist and are utilized by different apoptosis-inducing 
agents. 
 
The mechanism by which NO regulates Bcl-2 ubiquitination is not known but may involve 
S-nitrosylation of the protein, which may prevent its recognition and subsequent attachment 
of ubiquitin by the enzyme ubiquitin ligases. S-Nitrosylation of proteins, such as FLIP and 
caspases, has been reported to modulate their apoptosis activities (19, 55-57). To determine 
the effect of NO on Bcl-2 ubiquitination and degradation, we analyzed NO-mediated S-
nitrosylation of Bcl-2 in Cr(VI)-treated cells. We found that Cr(VI) induced S-nitrosylation 
 60 
of Bcl-2 and that this effect was inhibited by the NO inhibitors AG and PTIO and enhanced 
by the NO donors SNP and PTIO (Fig. 5). Inhibition of S-nitrosylation by the known 
inhibitor DTT completely inhibited the effect of NO on Bcl-2 ubiquitination (Fig. 5D), thus 
confirming the protective role of S-nitrosylation on Bcl-2 ubiquitination. Recent evidence 
suggests that NO can nitrosylate E3 ubiquitin ligase (parkin, Mdm2) (60, 61). S-
Nitrosylation of this enzyme inhibits its activity and protective function. To test whether 
the effect of NO was due to S-nitrosylation of Bcl-2 specifically or due to nitrosylation of 
ubiquitin ligase, we performed a proteasome activity assay and tested the effect of DTT on 
the enzyme activity in the presence or absence of Cr(VI). We found that DTT had no 
significant effect on proteasomal activity as compared with Cr(VI) treatment alone (Fig. 
5D). If the effect on Bcl-2 degradation was due to S-nitrosylation of ubiquitin ligase, 
treatment with DTT should have shown an increase in proteasomal activity. This result 
suggests that the effect of NO on Bcl-2 stability was specifically due to S-nitrosylation of 
Bcl-2. This result was confirmed by mutation assay in which the cysteine residues of Bcl-2 
(Cys158 and Cys229) were mutated to alanines. Such mutations resulted in a complete 
inhibition of Bcl-2 S-nitrosylation by Cr(VI) (Fig. 7 and 8). The stronger inhibitory effect 
of the Cys229 mutation indicates that this cysteine is the major site of Bcl-2 S-nitrosylation. 
Further, cysteine mutations led to increased ubiquitination and increased apoptosis, 
confirming that S-nitrosylation of Bcl-2 prevents its ubiquitination and stabilizes the 
activity of the protein. Recent evidences suggest that under physiological conditions NO 
does not react with thiol (-SH) groups directly as it requires the presence of a strong 
electron acceptor such as Fe3+(63). The kinetically favored reaction for NO is interaction 
with ·O2‾ which leads to the formation of ONOO¯(64). NO derived reactive species such as 
ONOO¯ readily reacts with thiols to form nitrosothiols (RS-NO). As shown in the previous 
aim, we observed that ·O2‾ is the major ROS involved in Cr(VI)-induced apoptosis, we 
therefore tested the possibility of ONOO¯ involvement in S-nitrosylation of Bcl-2. We 
observed a direct correlation between NO and ·O2‾ levels, with the increase in one leading 
to the decrease in the levels of the other and vice versa (Fig. 9). We observed that ·O2‾ 
donor further increased Cr(VI) induced Bcl-2 S-nitrosylation and ·O2‾ inhibitors reduced it 
to the control levels. Further, SIN1 treatment decreased Cr(VI) induced apoptosis 
significantly. All these results suggest that ONOO¯ causes S-nitrosylation of Bcl-2 that 
leads to its stabilization (Fig. 10). 
 
Since this study shows a novel mechanism of Bcl-2 regulation by S-nitrosylation, we 
further tested the generality of this process by treating the cells with other well established 
stress inducers, including FasL and BSO. BSO is an amino acid that depletes cells of 
glutathione, resulting in free radical-induced apoptosis (65). FasL is a death ligand that is 
known to induce apoptosis via the death receptor pathway (48, 49). We observed that Bcl-2 
was S-nitrosylated in response to these stress inducers, suggesting that S-nitrosylation is a 
general process that can regulate Bcl-2 stability and function under various stress 
conditions (Fig. 6). In summary, our data provide evidence that NO plays an important role 
as a negative regulator of Cr(VI)-induced cell death through the mitochondrial pathway by 
preserving Bcl-2 stability and function. NO exerts this effect through the formation of 
ONOO¯, which nitrosylates the protein and inhibit its ubiquitination and proteasomal 
degradation. S-Nitrosylation of Bcl-2 was observed to be a general mechanism that can 
regulate its stability under various stress conditions. In demonstrating S-nitrosylation of 
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Bcl-2, we document a novel layer of regulation that links NO signaling with Bcl-2 stability 
and function, which may represent an important mechanism that controls cancer 
development and progression. Since increased NO production and Bcl-2 expression have 
been associated with several human tumors, NO may be one of the key regulators of cell 
death resistance and cancer development through its ability to S-nitrosylate Bcl-2. This 
finding on the novel function of NO on Bcl-2 regulation may have important implications 







































































FIGURE 1. Effect of NO modulators on Cr(VI)-induced apoptosis and caspase 
activation. A, subconfluent (90%) monolayers of H460 cells were pretreated with the NO 
donor SNP (500 µg/ml) or DPTA NONOate (400 µM) or with the NO inhibitor AG (300 
µM) or PTIO (300 µM) for 1 h. The cells were then either left untreated or treated with 
Cr(VI) (20 µM) for 12 h and analyzed for apoptosis by Hoechst assay. B, dose effect of NO 
modulators on Cr(VI)-induced apoptosis. Cells were treated with Cr(VI) (20 µM) for 12 h 
after pretreatment with SNP (250, 500, and 750 µg/ml), DPTA NONOate (200, 400, and 
600 µM), AG (100, 300, and 500 µM), or PTIO (100, 300, and 500 µM) for 1 h. C, cells 
were similarly treated with Cr(VI) with or without NO modulators, and caspase-9 activity 











































FIGURE 2. Effect of NO modulators on cellular NO levels. A and B, flow cytometric 
analysis of NO production in H460 cells. Cells were treated with the NO inhibitor AG (300 
µM) or PTIO (300 µM) or with the NO donor SNP (500 µg/ml) or DPTA NONOate (400 
µM) for 1 h, after which they were treated with Cr(VI) (20 µM) and analyzed for NO levels 
by flow cytometry using DAF DA as the fluorescent probe. Plots show relative DAF 
fluorescence intensity determined at the peak response time of 1 h after Cr(VI) treatment. 
C, fluorescence micrographs of treated cells from above. D, measurement of nitrite 
production (direct breakdown product of NO) by the Griess method. Cells were treated as 
mentioned above, and 50 µl of the culture medium in each plate was collected and analyzed 
for NO production by Griess method. Values are mean ± S.D. (n  ≥ 3). *, p   < 0.05 versus 


































FIGURE 3. Effect of NO modulators on Bcl-2 expression and phosphorylation. A, 
H460 cells were pretreated for 1 h with one of the following agents: SNP (500 µg/ml), 
DPTA NONOate (400 µM), AG (300 µM), PTIO (300 µM), and lactacystin (LAC) (10 
µM). The cells were then treated with Cr(VI) (20 µM) for 12 h, and cell lysates were 
prepared and analyzed for Bcl-2 expression by Western blots using anti-Bcl-2 antibody. B, 
H460 cells were treated with AG (300 µM) and PTIO (300 µM) for 12 h, and cell lysates 
were prepared and analyzed for Bcl-2 expression by Western blots using anti-Bcl-2 
antibody. C, H460 cells were pretreated for 1 h with SNP (500 µg/ml), DPTA NONOate 
(400 µM), AG (300 µM) and  PTIO (300 µM) and were then treated with Cr(VI) (20 µM) 
for 12 h, and cell lysates were prepared and analyzed for Bcl-2 phosphorylation by Western 
blots using phospho-specific Bcl-2 (Ser 87) antibody. Densitometry was performed to 
determine the relative levels of Bcl-2 and phospho-Bcl-2 after reprobing the blots with β-



























FIGURE 4. Effect of NO on Bcl-2 ubiquitination. Subconfluent monolayers of H460 
cells overexpressing Bcl-2 were pretreated with the NO inhibitor AG (300 µM) or PTIO 
(300 µM) or with the NO donor SNP (500 µg/ml) or DPTA NONOate (400 µM) for 1 h. 
Subsequently, the cells were treated with Cr(VI) (20 µM) for 3 h in the presence of 
lactacystin (10 µM) to prevent proteasome-mediated Bcl-2 degradation. Cell lysates were 
immunoprecipitated with anti-myc antibody, and the immune complexes were analyzed for 
ubiquitin by Western blotting. Analysis of ubiquitin was performed at 3 h post-Cr(VI) 
treatment, where ubiquitination was found to be maximal. Data are mean ±S.D. (n = 4). *, 












































FIGURE 5. Effect of NO on S-nitrosylation and ubiquitination of Bcl-2. A, subconfluent 
monolayers of H460 cells overexpressing Bcl-2 were pretreated with SNP (500 µg/ml), 
DPTA NONOate (400 µM), AG (300 µM), PTIO (300 µM), or DTT (10 mM) for 1 h. The 
cells were then treated with Cr(VI) (20 µM) for 3 h, and cell lysates were prepared for 
immunoprecipitation using anti-myc antibody. The resulting immune complexes were 
analyzed for S-nitrosocysteine by Western blotting. Densitometry was performed to 
determine the relative S-nitrosocysteine levels after reprobing the membranes with anti-
Bcl-2 antibody. B, S-nitrosylation of Bcl-2 determined by spectrofluorometry. 
Immunopellets from above were incubated with 200 µM HgCl2 and 200 µM DAN. NO 
released from S-nitrosylated Bcl-2 was quantified at 375/450 nm. C, effect of NO 
modulators and DTT on Cr(VI)-induced Bcl-2 ubiquitination. Cells overexpressing Bcl-2 
were treated with the indicated test agents in the presence of lactacystin (10 µM). Cell 
lysates were then immunoprecipitated with anti-myc antibody, and the immune complexes 
were analyzed for ubiquitin. D, cells overexpressing Bcl-2 were pretreated with DTT (10 
mM) for 0.5 h and then treated with Cr(VI) (20 µM) for 3 h. Proteasome activity was 
determined spectrofluorometrically at 380/460 nm. Data are mean ± S.D. (n = 4). *, p < 
0.05 versus non-treated control. **, p < 0.05 versus Cr(VI)-treated controls. #, p  < 0.05 
versus NO-modulated controls. 
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FIGURE 6. Effect of stress inducers on Bcl-2 S-nitrosylation. A, Subconfluent 
monolayers of H460 cells overexpressing Bcl-2 were treated with FasL (200 ng/ml), BSO 
(100 µM), or Cr(VI) (20 µM) for 3 h, and cell lysates were prepared for 
immunoprecipitation using anti-Myc antibody. The resulting immune complexes were 
analyzed for S-nitrosocysteine by Western blotting. Densitometry was performed to 
determine the relative S-nitrosocysteine levels after reprobing of the membranes with anti-
Bcl-2 antibody. B, S-nitrosylation of Bcl-2 determined by spectrofluorometry. 
Immunopellets from above were incubated with 200 µM HgCl2 and 200 µM DAN. NO 
released from S-nitrosylated Bcl-2 was quantified at 375/450 nm. Data are mean ± S.D. (n 











































FIGURE 7. Effect of cysteine mutations on S-nitrosylation of Bcl-2. A, H460 cells were 
transiently transfected with myc-tagged original Bcl-2 plasmid (WT) or with myc-tagged 
C158A, C229A, or C158A/C229A mutant plasmid. 36 h later, the cells were treated with or 
without Cr(VI) (20 µM) for 3 h, and cell lysates were prepared for immunoprecipitation 
using anti-myc antibody. The immune complexes were analyzed for S-nitrosocysteine by 
Western blotting. Densitometry was performed to determine the relative S-nitrosocysteine 
levels after reprobing of the membranes with anti-Bcl-2 antibody. B, S-nitrosylation of Bcl-
2 determined by spectrofluorometry. Immunopellets from above were incubated with 200 
µM HgCl2 and 200 µM DAN. NO released from S-nitrosylated Bcl-2 was quantified at 
375/450 nm. Data are mean ± S.D. (n = 4). *, p < 0.05 versus non-treated control; **, p < 
































FIGURE 8. Effect of cysteine mutations on ubiquitination of Bcl-2. A, H460 cells were 
transiently transfected with myc-tagged original Bcl-2 plasmid (WT) or with myc-tagged 
C158A, C229A, or C158A/C229A mutant plasmid. 36 h later, the cells were treated with or 
without Cr(VI) (20 µM) for 3 h, and cell lysates were prepared for immunoprecipitation 
using anti-myc antibody. Immunoprecipitates were prepared as described above and 
analyzed for ubiquitin by Western blotting. Data are mean ± S.D. (n = 4). B, H460 cells 
transfected with original (WT) and mutant plasmids as mentioned above were exposed to 





























                                            
 

















FIGURE 9. NO reacts with ·O2‾ to form ONOO‾. A, H460 cells were treated with ·O2‾ 
donor LY-83,583 and ·O2‾ scavenger MnTBAP for 0.5 h, after which they were treated 
with Cr(VI) (20 µM) and analyzed for NO levels by spectrofluorometry using DAF-DA as 
the fluorescent probe. B, Cells were treated with the NO inhibitor AG (300 µM) or PTIO 
(300 µM) or with the NO donor SNP (500 µg/ml) or DPTA NONOate (400 µM) for 0.5 h, 
after which they were treated with Cr(VI) (20 µM) and analyzed for ·O2‾  levels by 
spectrofluorometry using DHE as the fluorescent probe. Plots show relative DAF and DHE 
fluorescence intensity determined at the peak response time of 1 h after Cr(VI) treatment. *, 



































FIGURE 10. ONOO‾  inhibits apoptosis and causes S-nitrosylation of Bcl-2. A and B, 
subconfluent (90%) monolayers of H460 cells were exposed to Cr(VI) (20 µM) in the 
presence or absence of SIN-1 (100 µg/ml), and the cells were analyzed for apoptosis by 
Hoechst 33342 assay after 12 h exposure. E, Subconfluent monolayers of H460 cells 
overexpressing Bcl-2 were treated with LY 83,583 and MnTBAP followed by Cr(VI) (20 
µM) treatment for 3h, and cell lysates were prepared for immunoprecipitation using anti-
myc antibody. Immunopellets from above were incubated with 200 µM HgCl2 and 200 µM 
DAN. NO released from S-nitrosylated Bcl-2 was quantified at 375/450 nm by 
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Malignant Transformation of Human Lung Epithelial Cells in 
























Exposure to Cr(VI) is associated with the incidence of lung cancer in humans. Human lung 
cancer manifests mostly as epithelial cell derived carcinomas; however, it is still unknown 
whether human lung epithelial cells are directly susceptible to Cr(VI)-induced malignant 
transformation. This study was designed to determine whether the non-tumorigenic human 
lung epithelial Beas-2B cell line could be malignantly transformed in vitro by subjecting 
them to long-term Cr(VI) exposure. Additionally, human lung cancer epithelial H460 cells 
were used and the effects in Beas-2B cells were compared to this cell-type. Beas-2B and 
H460 cells were continuously exposed to 5 µM Cr(VI). After 24 weeks of exposure, Cr(VI) 
exposed cells exhibited loss of contact inhibition and increased colony formation in soft 
agar as compared to the passage-matched original cell-lines. Further, an increase in 
proliferation, invasion and migration rates was observed in the transformed cells. Cr(VI) 
transformed cells showed decreased ROS production and apoptosis as well as an increase 
in NO levels and inhibition of Bcl-2 down-regulation. This confirmed our earlier 
observations that dysregulation of ROS mediated Cr(VI)-induced apoptosis by NO through 
the stabilization of Bcl-2 is an important molecular event in the development of apoptosis 
resistant phenotype in response to Cr(VI) exposure. This is the first report demonstrating 
Cr(VI)-induced malignant transformation of a human lung epithelial cell line and provides 
an important in vitro model for studying the mechanisms involved Cr(VI)-induced 





























Lung cancer is the leading cause of cancer mortality worldwide, with over 1,000,000 
deaths annually (1). In US, 160,440 deaths were attributed to cancer of the lung and 
bronchus in 2003 (1, 2). Even though it is one of the major fatalities, the etiology of lung 
cancer remains poorly understood. Current research indicates that long-term exposure to 
inhaled carcinogens has the greatest impact on the risk of lung cancer. Inhalation of Cr(VI) 
compounds has been associated with the induction of human lung cancer for more than a 
century (3). In US, Machle and Gregorius reported the first epidemiologic evidence to 
demonstrate increased lung mortality among chromium-exposed workers (4). 
Subsequently, several epidemological studies in the last few decades have confirmed that 
exposure to Cr(VI) in chrome plating, electroplating, leather tanneries, pigment 
manufacturing and stainless steel welding is associated with the induction of lung cancer in 
workers employed in these industries (3, 5-7). In US,  an air quality survey indicated that 
people in several residential areas are exposed to particulate airborne chromium at 
concentrations exceeding 100 times the chronic toxicity benchmark (8). Therefore, in 
addition to occupational exposure, environmental chromium is an emerging concern and is 
associated with long-term carcinogenic effects of the lung. Even though several 
epidemiological studies have demonstrated the carcinogenic potential of Cr(VI) 
compounds, animal studies do not support this observation. Several groups have 
established in various animal models including rat, mice, guinea pigs and rabbits that 
exposure to Cr(VI) compounds demonstrated no significant increase in lung tumors with 
respect to the untreated control (9-11). The problems associated with the development of 
animal models to study Cr(VI)-induced carcinogenesis is poorly understood. Therefore, 
lack of a good model becomes a major hindrance in studying the molecular mechanisms 
involved in Cr(VI)-induced carcinogenesis. In this study, we developed an in vitro model 
for studying the molecular mechanisms underlying Cr(VI)-induced malignant 
transformation.  
 
The carcinogenic potential of chromium is attributed to various factors including chemical 
speciation, water solubility and intracellular reductive metabolism. Chromates with low 
solubility are less carcinogenic as compared to soluble chromates (12). Cr(VI) does not 
interact with the DNA directly. It has to be converted to Cr(III) inside the cell which then 
intercalates with the DNA causing DNA strand breaks, DNA-protein cross-links and Cr-
DNA adduct formation (13). In this process, ROS is generated that are believed to play an 
important role in the cytotoxicity induced by Cr(VI) (14) by causing cell cycle arrest, 
neoplastic transformation, and apoptosis induction (13, 15). It is well-established that 
dysregulated apoptosis contributes to tumor promotion, autoimmune and 
immunodeficiency diseases, and neurodegenerative disorders (16). Abnormal ROS 
generation and apoptosis regulatory mechanisms have been considered as the most 
important factors in neoplastic development in response to Cr(VI). Since human lung 
cancer manifests mostly as epithelial cell derived carcinomas (13), we used normal human 
lung epithelial Beas-2B cell-line and human lung cancer H460 cell-line for this study. 
Since it is not known whether Cr(VI) can directly transform human lung epithelial cells, we 
developed an in vitro model of Cr(VI)-induced lung carcinogenesis by subjecting the non-
 80 
tumorigenic human lung epithelial Beas-2B cell line to long-term Cr(VI) exposure in vitro. 
We also exposed human lung cancer epithelial H460 cells to Cr(VI) and compared the 
effects in Beas-2B cells to this cell-type. We observed that long-term exposure of Cr(VI) 
led to malignant transformation of the cells as exhibited by loss of contact inhibition, 
increase in colony formation, cell proliferation, invasion and migration. In the previous 
aims, we showed that ROS mediated Cr(VI)-induced apoptosis by the down-regulation of 
the anti-apoptotic protein Bcl-2. NO inhibited Cr(VI)-induced apoptosis by nitrosylating 
Bcl-2 protein that led to the stabilization and increased expression of Bcl-2 causing 
inhibition of apoptosis. Cr(VI) transformed cells showed decreased ROS production and 
apoptosis. They further demonstrated an increase in NO and inhibition of Bcl-2 down-
regulation verifying our earlier observations. The development of such an in vitro model 
allows detailed examination of the molecular changes underlying Cr(VI)-induced 
carcinogenesis in a system that is of clear relevance to human exposure and validates  

































4.3. Materials and Methods 
 
Chemicals and Reagents 
Sodium dichromate (Na2Cr2O7.2H2O) [Cr(VI)], 6-Anilinoquinoline-5,8-quinone (LY-
83,583), Hydrogen peroxide (H2O2), NO donor sodium nitroprusside (SNP), NO inhibitors 
aminoguanidine (AG) and 2-(4-carboxyphenyl)-4,4,5,5-tetramethyl-imidazoline-1-oxy-3-
oxide (PTIO) were obtained from Sigma Chemical Inc. (St. Louis, MO). Mn(III)tetrakis (4-
benzoic acid) porphyrin (MnTBAP) was purchased from Calbiochem (La Jolla, CA), and 
catalase was from Boehringer Mannheim (Indianapolis, IN). NO donor 
dipropylenetriamine (DPTA) NONOate was from Alexis Biochemicals (San Diego, CA). 
The oxidative probes, dichlorofluorescein diacetate (DCF-DA), dihydroethidium bromide 
(DHE), diaminofluorescien diacetate (DAF-DA) and the apoptosis dye Hoechst 33342 
were from Molecular Probes (Eugene, OR). Antibodies for Bcl-2 and peroxidase-labeled 
secondary antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). β-actin 
antibody was from Sigma (St. Louis, MO).  
 
Cell Culture 
The normal bronchial epithelial Beas-2B cell line and human lung cancer epithelial H460 
cell line were obtained from ATCC (Rockville, MD).  Beas-2B cells were cultured in 
DMEM media (Sigma, St. Louis, MO) containing 5% fetal bovine serum, 2 mM L-
glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin and H460 cells were 
cultured in RPMI 1640 medium (Sigma, St. Louis, MO) containing 5% fetal bovine serum, 
2 mM L-glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin in a 5% CO2 
environment at 37ºC. Cells were passaged at preconfluent densities using a solution 
containing 0.05% trypsin and 0.5 mM EDTA (Invitrogen).  
 
Derivation of transformed cells  
Beas-2B and H460 cells were exposed continuously to 5 µM Cr(VI) and incubated in a 5% 
CO2 environment at 37ºC. Cells were passaged weekly at preconfluent densities using a 
solution containing 0.05% trypsin and 0.5 mM EDTA (Invitrogen). Henceforth, Cr(VI) 
exposed cells are designated as B-Cr and H-Cr cells to distinguish them from the parental 
Beas-2B and H460 cells, respectively. Parallel cultures grown in Cr(VI) free medium 
provided passage-matched controls. After 24 weeks of exposure, phenotypic changes were 
observed in both B-Cr and H-Cr cells. The transformed cells were then grown in normal 
media and their tumorigenic potential was assessed by various experiments, described 
below. 
 
Cyquant cell proliferation assay 
Beas-2B, B-Cr, H460 and H-Cr cells were plated in a 96-well plate at a density of 1 × 104 
in growth media and were incubated for 24 h. The growth media was changed with 100 µl 
of 1X Cyquant dye binding solution (Invitrogen) and were incubated for 30-60 min at 
37°C. The fluorescence intensity of each sample was measured at 485/535 nm.  
 
Cell invasion and migration 
In vitro invasion and migration was determined by a modified Boyden chamber assay using 
cell culture inserts with a polycarbonate-filter coated with Matrigel (BD Biosciences, NJ) 
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for invasion or control inserts for migration in a 24-well format. Briefly, 3 × 104 cells 
(invasion) or 1.5 × 104 cells (migration) in 500 µl of serum-free media were added to the 
inserts. The lower chambers were filled with 5% FBS in media. Chambers were incubated 
at 37°C in a 5% CO2 atmosphere for 24 h for migration and 48 h for invasion. The non-
invading or non-migrating cells were removed from the insides of the inserts by cotton 
swabs. The cells that invaded the matrigel or migrated to the underside of the coated 
membrane were fixed and stained with Diff-Quik fixative and stain. The cell nuclei stain 
purple and the cytoplasm stains pink. The inserts were directly examined under a light 
microscope and the number of cells migrated or invaded was counted.  
 
Soft agar colony assay 
Soft agar assays were performed as described previously with minor modifications (17). 
Beas-2B, B-Cr, H460 and H-Cr cells (3 × 104 cells for each cell-type) were mixed with 
tissue culture media containing 0.5 % agar to result in a final agar concentration of 0.33 %. 
Cell suspension (1.5 ml) was immediately plated in 60 mm dishes coated with 7 ml/plate of 
0.5 % agar in tissue culture media. After 2 weeks, the number of colonies per 3 x 104 cells 
were counted under a light microscope.  
 
Apoptosis Assay 
After specific treatments, apoptosis was determined by incubating the cells with 10 µg/ml 
Hoechst 33342 nuclear stain for 30 min at 37°C and scoring the percentage of cells having 
intensely condensed chromatin and/or fragmented nuclei by fluorescence microscopy 
(Axiovert 100; Carl Zeiss) using Pixera software. 
 
ROS and NO Detection 
Intracellular peroxide, ·O2‾ and NO production were determined by spectrophotometry 
using DCF-DA, DHE or DAF-DA fluorescence probes, respectively.  Cells (1x106/ml) 
were incubated with the fluoresecent probes (10 µM) for 30 min at 37ºC, after which they 
were washed with PBS, and analyzed for DCF (494/519 nm), DHE (535/617 nm) or DAF 
(488/ 538nm) fluorescence using FLUOstar OPTIMA (BMG Inc., Durham, NC). 
 
Western Blotting 
After specific treatments, cells were incubated in lysis buffer containing 20 mM Tris-HCl 
(pH 7.5), 1% Triton X-100, 150 mM NaCl, 10% glycerol, 1 mM Na3VO4, 50 mM NaF, 
100 mM PMSF, and a commercial protease inhibitor mixture (Roche) for 20 min on ice.  
After insoluble debris was precipitated by centrifugation at 14,000 x g for 15 min at 4oC, 
the supernatants were collected and assayed for protein content using BCA method (Pierce 
Biotechnology, Rockford, IL).  Equal amount of proteins per sample (15 µg) were resolved 
on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred onto 0.45-µm nitrocellulose membrane (Pierce).  The transferred membranes 
were blocked for 1 h in 5% non-fat dry milk in TBST (25 mM Tris-HCl pH 7.4, 125 mM 
NaCl, 0.05% Tween-20) and incubated with the appropriate primary antibodies and 
horseradish peroxidase-conjugated isotype-specific secondary antibodies. The immune 






Cr(VI)-Induced Malignant Transformation of Normal Lung Epithelial Cells – Normal 
human bronchial epithelial cells Beas-2B were continuously exposed to 5 µM Cr(VI) and 
were passaged weekly. After 24 weeks of exposure, phenotypic differences were observed 
between the Cr(VI)-treated and passage-matched control cells. The treated cells, designated 
as B-Cr, were subsequently cultured in Cr(VI)-free medium and soon began to form cell 
mounds, even when subconfluent, whereas mounding was not observed in passage-
matched control cells (Fig. 1). This mounding indicated loss of contact inhibition and was 
the first indication of the transformation of Beas-2B cells. This was also observed in the 
cancer cell line used. As expected, cell mounding was observed in passage-matched control 
lung cancer epithelial H460 cells; however, treatment with Cr(VI) led to increased 
malignant transformation of the H460 cells. Cr(VI) transformed cells were stained with 
Hoechst stain to elucidate the colony formation clearly (Fig.1). As seen in the figure normal 
Beas-2B cells undergo malignant transformation leading to colony formation and loss of 
contact inhibition. Loss of contact inhibition is a characteristic in vitro feature of tumor 
progression (18). 
 
Confirmation of Cr(VI)-Induced Malignant Transformation – Soft agar colony formation 
assay was performed to confirm Cr(VI)-induced malignant transformation (Fig. 2). Beas-
2B, B-Cr, H460 and H-Cr cells were subjected to colony formation by growing them on 
agar plates as described in Materials and Methods to assess anchorage independent growth. 
After 2 weeks, B-Cr cells showed a 4 fold increase in colony formation as compared to the 
Beas-2B cells and H-Cr cells showed a 2 fold increase in colony formation as compared to 
the H460 cells (Fig. 2, A and B). These experiments demonstrated significant colony 
formation in Cr(VI) transformed cells, although very small, slowly growing colonies were 
also formed by normal human lung epithelial Beas-2B cells. It was also observed that the 
number of colonies formed by B-Cr cells were approximately equal to the number of 
colonies formed by the passage controlled H460 cells, indicating the carcinogenic potential 
of normal human lung epithelial cells, as H460 is a cancer cell-line. 
 
Effect of Cr(VI)-Induced Malignant Transformation on Cellular Proliferation – We further 
examined the proliferation of control and Cr(VI)-transformed lung epithelial cells in a 
complete medium. The transformed B-Cr cells proliferated approximately twice as fast as 
the control cells (Fig. 3), in keeping with their malignant behavior. Although H460 cells are 
lung cancer epithelial cells, exposure to Cr(VI) transformed this cell-line, further making it 
more malignant. H-Cr cells proliferated slightly faster than H460 cells. Overall, the 
transformed cells showed rapid growth as compared to the original cell-lines.  
 
Effect of Cr(VI)-Induced Malignant Transformation on Cellular Invasion and Migration – 
Cr(VI) exposed cells were assessed in vitro for the potential to migrate through and invade 
matrigel. The invasive and migratory properties of the transformed cells were compared to 
the original cell-lines. B-Cr cells demonstrated approximately 4.5 fold increase in invasion 
and nearly 4 fold increase in the migration rate as compared to passage-matched Beas-2B 
cells (Fig. 4A). H-Cr cells demonstrated more than 5 fold increase in invasion and 4.5 fold 
increase in the migration rate as compared to passage-matched H460 cells (Fig. 4A). This 
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result indicated the aggressive and malignant nature of the Cr(VI) transformed cells.   
 
Apoptosis Levels in Cr(VI) Transformed Cells – Dysregulation of apoptosis regulatory 
mechanisms in response to Cr(VI) exposure has been implicated in Cr(VI)-induced 
malignant transformation (19). Therefore, to study the mechanism involved in Cr(VI) 
induced malignant transformation, we characterized the apoptotic response in transformed 
cells as compared to normal cells. Cells were treated with different doses of Cr(VI) (0-100 
µM), and apoptosis was determined after 12 h by Hoechst 33342 assay. Figs. 5, A and B, 
show that Cr(VI) treatment caused a dose-dependent increase in cell apoptosis in Beas-2B 
and H460 cells and, comparatively, B-Cr and H-Cr cells demonstrated reduced apoptosis. 
This indicated that continuous exposure of Cr(VI) modifies cellular system such that the 
damaged cells escape apoptosis and undergo malignant transformation.  
 
Cellular ROS Levels in Cr(VI) Transformed Cells – As demonstrated in aim II, Cr(VI) 
induced ROS production is involved in apoptosis induction. Since we observed a decrease 
in apoptosis in Cr(VI) transformed cells, we quantified the ROS levels in these transformed 
cells. When we treated B-Cr and H-Cr cells with Cr(VI), we observed that hydroperoxide 
and ·O2‾ production was significantly reduced as compared to Beas-2B and H460 cells in a 
dose-dependent manner, as indicated by the decrease in DCF and DHE fluorescence 
intensity (Figs. 6, A-D). This observation was verified by treating cells with various ROS 
modulators along with Cr(VI). ROS modulators showed significantly decreased ROS levels 
in Cr(VI) transformed cells as compared to the passage-matched control cell-lines (Fig. 7, 
A-D). This suggests that cells acquire apoptosis resistant phenotype by decreasing ROS 
production that leads to decreased apoptosis in response to Cr(VI). 
 
Cellular NO Levels in Cr(VI) Transformed Cells – We demonstrated in aim III that NO 
inhibits Cr(VI)-induced apoptosis by nitrosylating and stabilizing Bcl-2 protein. Therefore, 
NO regulates cellular events such that cells become resistant to apoptosis. NO mediated 
regulation of Cr(VI)-induced apoptosis may be a key mechanism by which cells acquire 
apoptosis resistant phenotype. To test this possibility we quantified the NO levels in Cr(VI) 
transformed cells as compared to the passage-matched control cells. It was observed that 
NO production induced in response to Cr(VI) in Beas-2B and H460 cells was further 
increased significantly in B-Cr and H-Cr cells in a dose-dependent manner, as indicated by 
the increase in DAF fluorescence intensity (Figs. 8, A and B). Further, NO modulation 
studies confirmed this result (Fig. 8, C and D). This indicated that malignant transformation 
involves increased NO production and thus confirmed our earlier study that NO exerts an 
anti-apoptotic role in response to Cr(VI) exposure. 
 
Bcl-2 Expression Levels in Cr(VI) Transformed Cells – The oncogenic potential of Bcl-2 is 
well-established with its overexpression reported in various cancers including lung cancer 
(20-24). In our earlier aims, we found that Bcl-2 is the key anti-apoptotic protein involved 
in inhibiting Cr(VI)-induced apoptosis. Having demonstrated the important role of Bcl-2 in 
Cr(VI)-induced apoptosis, we examined the potential modification of Bcl-2 expression in 
Cr(VI) transformed cells. To provide a mechanistic insight into the dysregulation of 
Cr(VI)-induced apoptosis, the expression level of Bcl-2 in response to Cr(VI) treatment 
was determined in B-Cr and H-Cr cells as compared to Beas-2B and H460 cells by 
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Western blot analysis. Figs. 9, A and B show that Bcl-2 is down-regulated in Beas-2B and 
H460 cells, however this effect was reversed and Bcl-2 was stabilized in B-Cr and H-Cr 
cells. This suggested that persistent and long-term exposure to Cr(VI) leads to the 
stabilization and overexpression of the anti-apoptotic protein Bcl-2 that causes inhibition of 













































Cr(VI) is a known human carcinogen that induces lung cancer (3, 5-7). Several 
epidemiological studies have demonstrated the carcinogenic potential of Cr(VI) 
compounds. However, the mechanisms involved in Cr(VI) induced carcinogenesis are 
poorly understood. One of the major hindrances is the lack of an appropriate model for 
studying Cr(VI) induced malignant tranformation because exposure to Cr(VI) does not 
induce lung tumor formation in animals (9-11). Since there is no direct evidence 
demonstrating the carcinogenic potential of Cr(VI), we developed an in vitro model of 
Cr(VI)-induced lung carcinogenesis by subjecting the non-tumorigenic human lung 
epithelial Beas-2B cell line to long-term Cr(VI) exposure in vitro. In addition, we also 
exposed human lung cancer epithelial H460 cells to Cr(VI) further transforming these cells 
and compared the effects in Beas-2B cells to the control and transformed H460 cells to 
validate our observations. We observed that long-term exposure of these cells to Cr(VI) led 
to malignant transformation of the cells as observed by the loss of contact inhibition in 
vitro of the non-tumorigenic human lung epithelial Beas-2B cell-line (Fig.1). This is an 
exclusive property of cancer cells and demonstrates the malignant transformation of normal 
cells in response to Cr(VI) exposure. B-Cr and H-Cr cells demonstrated anchorage-
independent growth and increased colony formation in soft agar as compared to the 
passage-matched original cell-line confirming the malignant potential of Cr(VI) 
transformed cell-lines (Fig. 2). The number of colonies formed by B-Cr was comparable to 
the number of colonies formed by H460 cells confirming the carcinogenic potential of 
Cr(VI) transformed Beas-2B cells. Although Beas-2B cells are normal human bronchial 
epithelium obtained from autopsy of non-cancerous individuals, they also developed 
significantly less number of slow growing colonies. Beas-2B cells are widely reported to 
possess mutated and non-functional p53 gene (tumor suppressor gene) (25, 26) and ATCC 
product datasheet indicates that Beas-2B cell-line forms colonies in semisolid medium but 
were non-tumorigenic in immunosuppressed mice. Therefore, the colony formation 
observed in Beas-2B cells is due to inherent cell properties and not due to its tumorigenic 
potential. Cr(VI) transformed cells demonstrated an increase in the proliferation, invasion 
and migration rates as compared to the passage-matched control cells demonstrating their 
aggressive and malignant behavior (Fig. 3 and 4).  
 
We further characterized the mechanism involved in the malignant transformation of 
normal lung epithelial cells in response to Cr(VI) exposure. We have earlier shown that 
Cr(VI) induces apoptosis through the mitochondrial pathway and Bcl-2 plays an important 
role in this system. ROS mediates Cr(VI)-induced apoptosis by the down-regulation of the 
anti-apoptotic Bcl-2 protein and NO inhibited this effect by S-nitrosylating the protein that 
led to the stabilization and increased expression of Bcl-2 causing inhibition of apoptosis. 
Therefore, we tested the possibility of the involvement of this mechanism in Cr(VI) 
induced malignant transformation. We observed that the transformed cells showed 
decreased ROS production and increased NO production (Fig. 6, 7 and 8). Moreover, it was 
observed that apoptosis was inhibited and Bcl-2 was up-regulated in the Cr(VI) 
transformed cells (Fig. 5 and 9). These observations in the Cr(VI) transformed cells 
confirmed our earlier studies and revealed one of the important mechanisms responsible for 
Cr(VI)-induced malignant transformation. This study is important because it is the first, to 
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our knowledge, description of Cr(VI)-induced malignant transformation of a human lung 
epithelial cell-line analogous to a potential in vivo target cell population relevant to Cr(VI)-
induced carcinogenesis in humans. This study is also biologically significant, as there is 
established epidemiologic evidence that human lung is a potential target of Cr(VI) induced-
carcinogenicity. More importantly, it provides a model in which the molecular and genetic 
events associated with Cr(VI)-induced carcinogenesis in humans can be studied. Since 
Cr(VI) is a paradigm of carcinogenic transition metals, the inferences from this study may 







































































FIGURE 1. Cr(VI)-induced malignant transformation of normal human lung 
epithelial cells. Normal human bronchial epithelial Beas-2B cells were exposed to 5 µM 
Cr(VI) for 24 weeks. A, Passage-matched control Beas-2B and B-Cr cells stained with 
Hoechst 33342 dye (top). Passage-matched control Beas-2B and B-Cr cells under light 


















































FIGURE 2. Cr(VI)-induced malignant transformation assessed by Soft Agar colony 
formation. A, Beas-2B, B-Cr, H460 and H-Cr cells (3 x 104 cells) were seeded on 0.5 % 
agar plates and were incubated at 37oC in a 5% CO2 incubator. After 2 weeks, colonies 
were scored under a light microscope. B, Representative micrographs of colonies formed 
by Beas-2B, B-Cr, H460 and H-Cr cells in soft agar. Values are mean ± S.D. (n > 3). *, p < 




























FIGURE 3. Effect of Cr(VI)-induced malignant transformation on cellular 
proliferation. Beas-2B, B-Cr, H460 and H-Cr cells were plated in a 96-well plate at a 
density of 1 × 104 in growth media and were incubated for 24 h. The growth media was 
changed with 100 µl of 1X Cyquant dye binding solution and were incubated for 30-60 min 
at 37°C. The fluorescence intensity of each sample was measured at 485/535 nm. Values 
























































FIGURE 4. Effect of Cr(VI)-induced malignant transformation on cellular invasion 
and migration. A and B, Beas-2B, B-Cr, H460 and H-Cr cells at a density of 3 × 104 or 1.5 
× 104 cells/ml were added to inserts coated with matrigel (invasion) or control inserts 
(migration), respectively. The inserts were incubated for 48 h for invasion assay and 24 h 
for migration assay. Cells were counted under fluorescence microscope after staining and 
the average number of cells was scored in each case. Values are mean ± S.D. (n > 3). *, p < 
0.05 versus the respective passage-matched control cells. C, Representative micrographs of 
































FIGURE 5. Apoptosis in Cr(VI) transformed cells. A and B, subconfluent (90%) 
monolayers of Beas-2B, B-Cr, H460 and H-Cr cells were exposed to varying doses of 
Cr(VI) (0-100 µM) for 12 h, and the cells were analyzed for apoptosis by Hoechst 33342 
















































FIGURE 6. Cellular ROS levels in Cr(VI) transformed cells. A, B, C and D - 
spectrophotometric measurements of DHE and DCF fluorescence intensities in Beas-2B, 
B-Cr, H460 and H-Cr cells. Cells were treated with Cr(VI) (0-100 µM) for 1 h. Plots show 
relative fluorescence intensity over non-treated control. Values are mean ± S.D. (n > 3). E, 
F, G and H, Beas-2B, B-Cr, H460 and H-Cr cells were either left untreated or pretreated 
with MnTBAP (100 µM), catalase (10000 U/ml), LY-83,583 (10 µM) or H2O2 (0.1 mM) 
for 0.5 h, followed by Cr(VI) treatment (20 µM) for 1 h . Plots show relative fluorescence 








































FIGURE 7. Effect of ROS modulators on Cr(VI) transformed cells. A, B, C and D - 
spectrophotometric measurements of DHE and DCF fluorescence intensities in Beas-2B, 
B-Cr, H460 and H-Cr cells. Cells were treated with Cr(VI) (0-100 µM) for 1 h. Plots show 
relative fluorescence intensity over non-treated control. Values are mean ± S.D. (n > 3). E, 
F, G and H, Beas-2B, B-Cr, H460 and H-Cr cells were either left untreated or pretreated 
with MnTBAP (100 µM), catalase (10000 U/ml), LY-83,583 (10 µM) or H2O2 (0.1 mM) 
for 0.5 h, followed by Cr(VI) treatment (20 µM) for 1 h . Plots show relative fluorescence 








































FIGURE 8. Cellular NO levels in Cr(VI) transformed cells. A and B - 
spectrophotometric measurement of DAF fluorescence in Beas-2B, B-Cr, H460 and H-Cr 
cells. Cells were treated with Cr(VI) (0-100 µM) for 1 h. Plots show relative fluorescence 
intensity over non-treated control. C and D, Beas-2B, B-Cr, H460 and H-Cr cells were 
pretreated for 0.5 h with SNP (500 µg/ml), DPTA NONOate (400 µM), AG (300 µM), and 
PTIO (300 µM). The cells were then treated with Cr(VI) (20 µM) for 1 h and  were 
analyzed for DAF fluorescence. Plots show relative fluorescence intensity over non-treated 




































FIGURE 9. Bcl-2 expression in Cr(VI) transformed cells. A and B, Beas-2B, B-Cr, H460 
and H-Cr cells were treated with Cr(VI) for 12 h, and cell lysates were prepared and 
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 Both extrinsic and intrinsic pathways of apoptosis are induced in human lung 
epithelial cells in response to Cr(VI) exposure, with the mitochondrial pathway 
being more dominant. 
 
 Overexpression of the mitochondrial anti-apoptotic protein Bcl-2 significantly 
inhibits Cr(VI)-induced apoptosis. 
 
 ROS, specifically ·O2‾, is important in mediating apoptosis in response to Cr(VI) 
exposure.  
 
 Mitochondrion is the main source of ROS production during Cr(VI)-induced 
apoptosis. 
 
 ·O2‾ induces apoptotic cell death, at least in part, by inducing proteasomal 
degradation of Bcl-2 protein in response to Cr(VI) exposure. 
 
 NO plays an anti-apoptotic role in Cr(VI)-induced apoptosis.  
 
 NO mediates its effect, at least in part, by the inhibition of proteasome-mediated 
degradation of Bcl-2. 
 
 The mechanism by which NO regulates Bcl-2 involves S-nitrosylation of the 
protein, which was also observed under other stress conditions, including exposure 
to death ligand and glutathione depletion. 
 
 NO mediated ONOO¯ is the major reactive nitrogen species involved in S-
Nitrosylation of Bcl-2 that prevents its downregulation via the ubiquitin-proteasome 
pathway.  
 
 Both Cys158 and Cys229 are involved in S-nitrosylation and ubiquitination of Bcl-2, 
with Cys229 being the major site for nitrosylation.  
 
 Chronic Cr(VI) exposure can induce malignant transformation of normal human 
lung epithelial cells. 
 
 The in vitro model of Cr(VI)-induced malignant transformation verified that the 
molecular mechanisms recognized in our study are important in Cr(VI)-induced 
carcinogenesis. 
 
 Cr(VI)-induced malignant transformation of human lung epithelial cells is of clear 
relevance to human exposure and validates  human lung epithelial cells as a direct 
target for Cr(VI)-induced carcinogenesis. 
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Pharmaceutical Sciences, West Virginia University. 
 
 Synthesized and characterized CYP2D6.N, a novel isoform of CYP2D6 sub-family 
of cytochrome P450s (major drug metabolizing enzymes). 
 
• Jun 2000 - Jul 2000 – Summer internship at Meyer Organics Ltd – Mumbai, India. 
  
 Worked in production, quality control, marketing, research and development 
departments. 
 Worked on tablet coating and quality control of a syrup formulation. 
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 Neelam Azad, Wang L., Rojanasakul Y. – Signaling Cascades in Cr(VI)- induced 
Apoptosis AAPS, 2004.    
 Neelam Azad, Vallyathan V., Wang L., Rojanasakul Y. – Role of Nitric Oxide in 
Cr(VI)-induced Apoptosis. AAPS, 2004.   
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 Student member of the American Association of Pharmaceutical Scientists (AAPS) 
since 2004. 
 Honorary member of Sigma Xi Research Society since 2006.  
 
